

AWARD NUMBER: W81XWH-18-1-0113

TITLE: Modifying Heterocycles to Treat Gram + and Gram - Bacteria

PRINCIPAL INVESTIGATOR: Martin Conda-Sheridan

CONTRACTING ORGANIZATION: University of Nebraska Medical Center
Omaha, NE 68198

REPORT DATE: May 2019

TYPE OF REPORT: Annual

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

REPORT DOCUMENTATION PAGE				Form Approved OMB No. 0704-0188	
Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS.					
1. REPORT DATE May 2019		2. REPORT TYPE Annual		3. DATES COVERED 1 May 2018 - 30 Apr 2019	
4. TITLE AND SUBTITLE Modifying Heterocycles to Treat Gram + and Gram - Bacteria				5a. CONTRACT NUMBER	
				5b. GRANT NUMBER W81XWH-18-1-0113	
				5c. PROGRAM ELEMENT NUMBER	
6. AUTHOR(S) Martin Conda Sheridan, PhD E-Mail:martin.condasheridan@unmc.edu				5d. PROJECT NUMBER	
				5e. TASK NUMBER	
				5f. WORK UNIT NUMBER	
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) University of Nebraska Medical Center 42nd and Emile, Omaha, NE 68198				8. PERFORMING ORGANIZATION REPORT NUMBER	
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012				10. SPONSOR/MONITOR'S ACRONYM(S)	
				11. SPONSOR/MONITOR'S REPORT NUMBER(S)	
12. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited					
13. SUPPLEMENTARY NOTES					
14. ABSTRACT Bacterial infections are a serious threat to human health. During the award period we focused on the synthesis of some phenazines with potential antimicrobial activity. Our hypothesis is the conjugation of amines, polyamines and peptides to the phenazines will enhance their activity. We achieve the synthesis of several new phenazines containing diverse functional groups. Most of the new compounds presented modest antibacterial activity, thus, a structural optimization is being performed using the obtained data. The attachment of amines to the active phenazines proved difficult due to a rearrangement that took places. Thus, we focused in optimizing the structure of potential peptides that can be added to the phenazines. We prepared and evaluated some intriguing new peptides that presented potent activity against a panel of gram positive and gram negative pathogens. We also identified some key features that give rise to their activity. Over the next year we will focus on creating phenazine-peptide conjugates as novel antibacterials.					
15. SUBJECT TERMS Phenazines, antibacterials, antimicrobial peptides, antibacterial hybrids, gram positive, gram negative					
16. SECURITY CLASSIFICATION OF: U			17. LIMITATION OF ABSTRACT UU	18. NUMBER OF PAGES 39	19a. NAME OF RESPONSIBLE PERSON USAMRMC
a. REPORT U Unclassified	b. ABSTRACT U Unclassified	c. THIS PAGE U Unclassified			19b. TELEPHONE NUMBER (include area code) 402-559-9361

Table of Contents

	<u>Page</u>
1. Introduction.....	4
2. Keywords.....	4
3. Accomplishments.....	4
4. Impact.....	9
5. Changes/Problems.....	9
6. Products, Inventions, Patent Applications, and/or Licenses.....	11
7. Participants & Other Collaborating Organizations.....	12
8. Special Reporting Requirements.....	14
9. Appendices.....	

I. INTRODUCTION:

The goal of this project is to prepare new members of the phenazine family of heterocycles and to enhance their antimicrobial action by conjugating amines, polyamines, and peptides. **The working hypothesis is** that these hybrid molecules will present broad spectrum of antibacterial activity and will possess enhanced penetration inside gram negative bacteria. The increased accumulation of the antimicrobial drugs will promote bacterial killing. We theorize this is a preferred strategy than uptake thru porins. Please note in the case of the polyamines or peptides the penetration inside the bacteria will be achieved by the membrane disruption caused by these segments. Because we will damage a protective barrier within the pathogen while permitting then entrance of the antibiotic agent our expectation is bacteria will have a harder time to develop resistance because two mechanisms of killing will be operational.

II. KEYWORDS:

Phenazines, antibacterials, antimicrobial peptides, antibacterial hybrids, gram positive, gram negative.

III. ACCOMPLISHMENTS:

○ What were the major goals of the project?


The major goals were: (1) the synthesis of new phenazines; (2) the synthesis of new peptides; (3) the synthesis of phenazine-XX hybrids (XX = amines, polyamines, or peptides); (4) the biological evaluation of the entities described in points 1-3 in vitro and in vivo.

○ What was accomplished under these goals?

1) Major activities. During this period we worked on optimizing the procedures that relate to the synthesis, purification, and characterization of phenazines and peptides.

2) Specific objectives. To develop a simple synthetic protocol for the preparation of the molecules. To identify potent leads that can be modified and the points of modification of these compounds. Also, to explore groups and atoms that facilitate conjugation.

3) Significant results or key outcomes, including major findings, developments, or conclusions (both positive and negative). We were able to prepare approximately 20 phenazines (Table 1) but none of those molecules presented interesting antibacterial activity. The synthetic protocol for one of the compounds is shown below.



Reagents and Conditions: (a) (i) DPPA, Et₃N, THF, rt (ii) H₂O, reflux; (b) TFAA, Et₃N, CH₂Cl₂, 0 °C to rt; (c) CH₃COCl, Et₃N, CH₂Cl₂, 0 °C to rt.


N-(9-Chlorophenazin-1-yl)acetamide (3b). To a stirred solution of **10** (0.05 g, 0.22 mmol) in CH₂Cl₂ (5 mL) were added triethyl amine (61 μL, 0.44 mmol) and acetyl chloride (17 μL, 0.24 mmol) at 0 °C. The reaction mixture was stirred at room temperature for 4 h. The solvent was removed under vacuum and the

residue was purified by flash chromatography using Hexane/EtOAc (1:9) as a eluent to afford the titled product as a yellow solid (21 mg, 36%); mp: 213–215 °C; ^1H NMR (CDCl_3 , 500 MHz): 9.87 (br s, 1 H), 8.87 (d, $J = 7.5$ Hz, 1 H), 8.22 (dd, $J = 8.5, 1.5$ Hz, 1 H), 8.0 (d, $J = 8.5$ Hz, 1 H), 7.93–7.82 (m, 2 H), 7.81 (t, $J = 7.5$ Hz, 1 H), 2.46 (s, 3 H); ^{13}C NMR (CDCl_3 , 125 MHz): 168.9, 144.2, 143.4, 137.6, 134.4, 134.1, 132.8, 132.7, 130.1, 129.9, 128.7, 122.7, 116.4, 25.1; ESIMS calcd for $\text{C}_{14}\text{H}_{11}\text{ClN}_3\text{O}$: 272.0591 (MH^+); found: 272.0812 (MH^+); HPLC purity 99.61%.

Table 1. Selected synthesized phenazines (all showed activities >32 $\mu\text{g/mL}$ against *S. aureus* JE2 and *E. coli* K12)

	R ₁	R ₂	R ₃	R ₄	R ₅
		H	H	H	CO_2H
	Cl	H	H	H	CO_2H
	Cl	H	H	H	NH_2
	Cl	H	H	H	NHCOCF_3
	Cl	H	H	H	NHCOCH_3
	H	H	H	H	Cl
	H	H	H	H	Br
	H	H	H	H	$\text{S}(\text{CH}_3)_3$
	H	H	H	H	SCH_3
	H	H	H	H	SH
	H	H	H	H	CO_2H
	Br	H	H	H	CO_2H
	F	H	H	H	CO_2H
	OCH_3	H	H	H	CO_2H
	CH_3	H	H	H	CO_2H
	Cl	H	H	Cl	CO_2H
	Br	H	H	OCH_3	CO_2H
	OCH_3	H	H	OCH_3	CO_2H
	H	H	H	Br	CO_2H
	H	H	Br	H	CO_2H
	H	H	OCH_3	H	CO_2H
	Br	H	OCH_3	H	CO_2H
	H	H	OCH_3	H	CO_2CH_3
	Br	H	OCH_3	H	CO_2CH_3
	Cl	H	H	H	CONH_2

We also prepared some sulfonamide derivatives as shown below.



Reagents and conditions: (a) TCFH, NMI, ACN, rt. 2h to 24 h

The data for the thiophene derivative is next: ^1H NMR (CDCl_3) δ : 14.41 (s, 1 H), 9.98 (d, $J = 6.5$ Hz, 1H), 8.51 (d, $J = 7.5$ Hz, 1H), 8.25 (d, $J = 9.0$ Hz, 1H), 8.12 (d, $J = 7.5$ Hz, 1H), 8.13-8.02 (m, 2H), 7.90 (t, $J = 7.5$ Hz, 1H), 7.67 (d, $J = 5.0$ Hz, 1H), 7.132 (d, $J = 4.5$ Hz, 1H); LCMS for $\text{C}_{17}\text{H}_{10}\text{ClN}_3\text{O}_3\text{S}_2$ [$\text{M}+\text{H}^+$] : 402.99, found 403.9.

4) Other achievements. We have proposed to attach the phenazines to some antimicrobial peptides. During the early evaluation of the project, we identified a natural peptide (known as citropin 1.1) with potent antibacterial activity. We proceeded to optimize its structure and found some analogues with potent antimicrobial action (active against gram positive and gram negative bacteria and fungi). We selected this peptide to generate the phenazine hybrids.

The table below presents the activity of citropin 1.1 (AMP-001) and its analogues.

Minimal inhibitory concentration (MIC) $\mu\text{g/mL}$								
Peptide sequence	Peptide code	<i>Sa</i> ^a	<i>Ec</i> ^b	<i>Pa</i> ^c	<i>Kp</i> ^d	<i>Ab</i> ^e	<i>Ca</i> ^f	<i>Cn</i> ^g
GLFDVIKKVASVIGGL	AMP-001	Ne	Ne	Ne	Ne	Ne	Ne	Ne
GLFDVI(Om)(Om)VASVIGGL	AMP-006	32	>32	>32	>32	>32	>32	32
GLFDVIRRVASVIGGL	AMP-012	16	32	>32	>32	32	16	16
GLFDVIRKVASVIGGL	AMP-013	16	>32	>32	>32	32	>32	16
GLFEVIKKVASVIGGL	AMP-015	32	>32	>32	>32	>32	>32	16
GLWDVIKKVASVIGGL	AMP-016	4	>32	>32	>32	16	32	8
GLWRVIRKVASVIGGL	AMP-017	4	4	>32	8	2	32	2
PhenylGlyLWDVIRKVASVIGGL	AMP-018	8	>32	>32	>32	32	32	8
GL(Biphenylalanine)DVIKKVASVIGGL	AMP-019	4	32	>32	>32	16	32	>32
GL(1-Nap)DVIKKVASVIGGL	AMP-020	4	32	>32	>32	16	32	>32
SarLWDVIRKVASVIGGL	AMP-021	8	16	>32	32	4	32	16

We found the antibacterial activity of the peptides is related to their ability to disrupt membranes.




Figure 1: SEM micrographs of *S. aureus* JE2 MRSA (up) and *E. coli* K12 (down) cells treated with **AMP-001** and **AMP-016** at twice MIC.

The cell membrane disruption of *S. aureus* and *E. coli* treated with AMPs at 2X MIC was further evaluated by

flow cytometry. Untreated (no AMPs) and treatment with EtOH (70%) were used as controls. After treatment (1 hr) with **AMP-001** and **AMP-016**, *S. aureus* cells showed an increased PI uptake compare to the untreated, indicating cell viability of 9.4% and 12.5%, respectively. *E. coli* cells with **AMP-001** and **AMP-016** showed viability of 13.9% and 27.5%, respectively.




Figure 2. PI uptake of AMPs. *S. aureus* JE 2 (A) and *E. coli* K12 (B) (1×10^7 CFU) were treated with AMPs (2X MIC) for 120 mins and the PI fluorescence intensity was measured. Polymyxyn B (PMB) at 16 $\mu\text{g/mL}$ final concentration was used as reference drug, which is known to kill Gram-negative bacteria by disrupting cell membrane.

NMR studies indicate the peptides form α -helices. The result was confirmed by circular dichroism (not shown)




Figure 3. The ensemble of the lowest energy, water refined structures of (A) **Cit 1.1**, (B) **AMP-016**. Peptide ribbon structures for (C) **Cit 1.1**, and (D) **AMP-016** are colored by the binned amide proton temperature titration data according to the ΔH ranges 0 to -0.05 (minor chemical shift, yellow), -0.05 to -0.25 (intermediate chemical

shift, orange), and -0.25 to -0.45 (major chemical shift, red). NOE connectivity plots for **(E) Cit 1.1**, and **(F) AMP-016**. Weights of the connectivities are normalized to the NOE intensities.

What opportunities for training and professional development has the project provided?

The funding provided ample training opportunities. Mr. Mohamed Seleem (graduate student) took a microbiology class which allowed him to enhance his knowledge of the subject. Moreover, he learned basic cell culture and microbiology protocols. Dr. Almeida (not supported by the grant) also expanded her theoretical and cellculture knowledge. Drs. Udumula and Krishnaiah enhanced their practical knowledge in peptide chemistry and theoretical knowledge in microbiology. In all cases, the knowledge was obtained by personal and group meetings, visits to other laboratories at UNMC (Dra. Ken Bayles and Scot Oullette), and by practical demonstrations performed by me or other members of my research group.

How were the results disseminated to communities of interest?

The results were presented in a conference and two seminars (as detailed below). In addition, the project was described in outreach activities. Specifically, we invited two troops of the Girl Scouts of America to visit the College of Pharmacy at the University of Nebraska medical Center (UNMC). We discussed the research we do and also explained the different options for science careers. I also presented the results to high school students participating in the UNMC-high school alliance program.

What do you plan to do during the next reporting period to accomplish the goals?

I will involve additional students in the project to obtain more results. Regarding dissemination, my goal is to present this research at an American Chemical Society National conference. Also, I will incorporate the results into the drug discovery class that I teach to high school students (outreach activity). I have hired two undergraduate students to work over the summer in my research laboratory. They will also work on this project, allowing them to obtain knowledge of organic synthesis and microbiology. I also plan to invite more troops from the Boys and Girls Scouts of America to visit our college to explain what we do and motivate them to pursue careers in science and technology.

IV. IMPACT: *Describe distinctive contributions, major accomplishments, innovations, successes, or any change in practice or behavior that has come about as a result of the project relative to:*

- **What was the impact on the development of the principal discipline(s) of the project?**

At this stage there is not much to report other than the fact we identified a peptide that can be conjugated to the phenazine and we were able to solve its secondary structure.

- **What was the impact on other disciplines?**

N/A

- **What was the impact on technology transfer?**

N/A

- **What was the impact on society beyond science and technology?**

N/A. However, I want to reiterate that troops from the Girl Scouts of America and their parents and high school students were introduced to the project. This is a way to educate future generations. In addition, our hope is the new phenazines and proposed hybrids can evolve into new therapies to treat bacterial infections.


V. CHANGES/PROBLEMS: *The Project Director/Principal Investigator (PD/PI) is reminded that the recipient organization is required to obtain prior written approval from the awarding agency Grants Officer whenever there are significant changes in the project or its direction. If not previously reported in writing, provide the following additional information or state, "Nothing to Report," if applicable:*

- **Changes in approach and reasons for change**


As stated, we have discovered a peptide that presented more potent antimicrobial action than the ones we originally proposed. Thus, we decided to use this peptide instead of the ones originally described on the grant.

- **Actual or anticipated problems or delays and actions or plans to resolve them**

We found some unexpected problems with the synthesis of the phenazines. Firstly, the coupling to the carboxylic acid did not proceed as expected. Secondly, a rearrangement took place.



Further, even though N-methylsulfonamide derivatives were easy to prepare, other members of the family presented serious challenges



Reagents and conditions: Shown in table below

Condition	Reaction success	Starting materials recovery
DCC, DIPEA, THF, rt. Overnight.	NO	NO
DCC, DIPEA, TEA, THF, 70 °C overnight to 3 days.	NO	NO
BYPOP, DIPEA, ACN, rt. overnight	NO	Yes
DIC, DIPEA, THF, rt. overnight		
TCFH, NMI, ACN, rt. 2h to 24h	Yes (with some derivatives)	Yes
Coupling followed by reductive cyclization	NO	NO
1) Oxalyl chloride, DCM, DMF, 30 °C 2) Sulfonamide derivative, DCM, TEA, r.t	NO	NO
DCC, OXYMA, DIPEA, THF, rt. Overnight.	NO	NO
TCFH, NMI, DCM, r.t 2h – 48h	NO	YES
TCFH, NMI, ACN, Microwave 40 °C, 10 min (3 cycles)	NO	NO (starting material decomposed)
TCFH, NMI, ACN/DCM, r.t 2h – 48h	NO	YES

- **Changes that had a significant impact on expenditures**

There was some significant turnover of personnel due to unforeseen circumstances: both postdocs found positions in other labs (one Emory, the other here in Nebraska). Also, both postdocs have personal problems (deaths of parents and divorce) that affected their performance and required them to be away. Finally, the graduate student had a baby and took some days off. That coupled to his graduate classes, affected productivity too.

- **Significant changes in use or care of human subjects, vertebrate animals, biohazards, and/or select agents**

N/A

- **Significant changes in use or care of human subjects**

N/A

- **Significant changes in use or care of vertebrate animals**

N/A

- **Significant changes in use of biohazards and/or select agents**

N/A

VI. PRODUCTS: *List any products resulting from the project during the reporting period. If there is nothing to report under a particular item, state "Nothing to Report."*

- **Publications, conference papers, and presentations**

- **Journal publications.**

Wood, N.; Chung, K.; Blocker, A.; Rodriguez de Almeida, N.; **Conda-Sheridan, M.**; Fisher, D.; Ouellette, S. Initial Characterization of the Two ClpP Paralogs of Chlamydia trachomatis Suggests Unique Functionality for Each. *J. Bacteriol.* **2018**, JB.00635-18

(This paper is not directly related to the project but Dr. Nathalia Rodrigues de Almeida and Mr. Mohamed Seleem learned valuable microbiology techniques in the laboratory of Dr. Scot Ouellette that will be used in the project. Dr. Almeida also prepared two molecules that could be used *in lieu of* the phenazines.)

Rodriguez de Almeida, N.; Catazaro, J.; Chhonker, Y.; Murry, D.; Powers, R.; **Conda-Sheridan, M.** Understanding the forces involved in membrane interactions of antibacterial peptides and their influence on biological activity and mechanics. Submitted to *peptides*

We are also writing a paper describing the synthesis and biological evaluation of the phenazines. We expect to finish the first draft within 3 months.

- **Books or other non-periodical, one-time publications.**

N/A

- **Other publications, conference papers, and presentations.**

Design, Synthesis, and Evaluation of Amphiphilic Peptides as New Antimicrobial Agents. Wichita State University, October 3, 2018. Host: Dennis Bruns

The Development of Small Molecule Antibacterials. DePaul University, September 14, 2018. Host: Charles Rubert Perez

Synthesis, Biological Evaluation, and Metabolic Studies of Phenazines, 2018 ACS-National Meeting, August 20, 2018. Host: Kyung Myung

- **Website(s) or other Internet site(s)**

N/A

- **Technologies or techniques**

N/A

- **Inventions, patent applications, and/or licenses**

N/A

- **Other Products**

N/A

VII. PARTICIPANTS & OTHER COLLABORATING ORGANIZATIONS

○ What individuals have worked on the project?

Name:	<i>Martin Conda-Sheridan</i>
Project Role:	<i>PI</i>
Researcher Identifier (e.g. ORCID ID):	0000-0002-3568-2545
Nearest person month worked:	<i>1 (9.5% effort)</i>
Contribution to Project:	<i>Dr. Conda-Sheridan supervised the project. He trained students and postdoctoral researchers on the synthetic aspect of the research, including purification and characterization of molecules. He reviewed the data</i>
Funding Support:	<i>The remaining of my salary came from an American Chemical Society-PRF grant, a NIH-COBRE, and the UNMC-college of Pharmacy.</i>

Name:	<i>Krishnaiah Maddeboina</i>
Project Role:	<i>Postdoctoral Fellow</i>
Researcher Identifier (e.g. ORCID ID):	0000-0003-2190-4378
Nearest person month worked:	<i>3 (2.7 months, 22.5% effort)</i>
Contribution to Project:	<i>Dr. Krishnaiah performed the synthesis, purification and characterization of some phenazines and peptides.</i>
Funding Support:	<i>The remaining of his salary was supported from an internal grant (from University of Nebraska) and NIH-COBRE.</i>

Name:	<i>Venkatareddy Udumula</i>
Project Role:	<i>Postdoctoral Fellow</i>
Researcher Identifier (e.g. ORCID ID):	
Nearest person month worked:	<i>3 (25% effort)</i>
Contribution to Project:	<i>Dr. Udumula performed the synthesis, purification and characterization of some phenazines.</i>
Funding Support:	<i>The remaining of his salary was supported from an internal grant (from University of Nebraska) and NIH-COBRE.</i>

Name:	<i>Nathalia Rodrigues de Almeida</i>
Project Role:	<i>Postdoctoral Fellow</i>
Researcher Identifier (e.g. ORCID ID):	0000-0002-9552-123
Nearest person month worked:	<i>1 (9.5% effort)</i>
Contribution to Project:	<i>Dr. Almeida performed the synthesis and purification of some peptides, also performed the characterization and antimicrobial evaluation. She taught other members of the group how to perform antibacterial assays.</i>
Funding Support:	<i>Her salary came from an internal grant (from University of Nebraska) and NIH-COBRE. She was not paid by this grant</i>

Name:	<i>Mohamed Seleem</i>
Project Role:	<i>Graduate Student</i>
Researcher Identifier (e.g. ORCID ID):	0000-0003-4379-5133
Nearest person month worked:	<i>12</i>
Contribution to Project:	<i>Mr Seleem performed the synthesis and purification of phenazines and peptides, he also performed the characterization and antimicrobial evaluation.</i>
Funding Support:	

- **Has there been a change in the active other support of the PD/PI(s) or senior/key personnel since the last reporting period?**

Nothing to Report.

- **What other organizations were involved as partners?**
 - **Organization Name:** Community for Open Antimicrobial Drug Discovery (CO-ADD) - The University of Queensland
 - **Location of Organization:** 306 Carmody Rd, The University of Queensland, St. Lucia, QLD, 4072, Australia
 - **Partner's contribution to the project** They performed the biological evaluation of selected molecules against ESKAPE pathogens (*E. coli*, *K. pneumoniae*, *A. baumannii*, *P. aeruginosa*, *S. aureus* (MRSA)) and fungi *C. neoformans* and *C. albicans*.
 - **Financial support;** Wellcome Trust

Nothing else to report

VIII. **SPECIAL REPORTING REQUIREMENTS**

○ **COLLABORATIVE AWARDS:**

N/A

○ **QUAD CHARTS:**

N/A

IX. **APPENDICES:** *Attach all appendices that contain information that supplements, clarifies or supports the text. Examples include original copies of journal articles, reprints of manuscripts and abstracts, a curriculum vitae, patent applications, study questionnaires, and surveys, etc. Reminder: Pages shall be consecutively numbered throughout the report. **DO NOT RENUMBER PAGES IN THE APPENDICES.***

Dr. Martin Conda-Sheridan
martin.condasheridan@unmc.edu
Assistant Professor
Department of Pharmaceutical Sciences
University of Nebraska-Medical Center

PDD 3016
986125 UNMC
Omaha, NE, 68198-5830
402-559-9361 (office)

Education

Ph.D. Medicinal Chemistry Purdue University, Department of Medicinal Chemistry, West Lafayette, IN Thesis: Design and synthesis of phenazines and indenoisoquinolines as cancer chemopreventive agents	2007–2012
M.S. Chemistry University of Utah, Department of Chemistry, Salt Lake City, UT	2005–2007
B.S. Chemistry Brigham Young University, Department of Chemistry, Provo, UT	2002–2005

Research and Work Experience

Assistant Professor, University of Nebraska Medical Center <ul style="list-style-type: none"> Synthesis and characterization of biomaterials with antibacterial properties Synthesis of anticancer drugs and antibacterial drugs 	2015–present
Postdoctoral Fellow, Northwestern University Prof. Samuel I. Stupp <ul style="list-style-type: none"> Synthesis and characterization of peptide-amphiphile nanostructures Design of enzyme-activated linkers for drug delivery 	2012–2015
Graduate Researcher, Purdue University Prof. Mark Cushman <ul style="list-style-type: none"> Synthesis and characterization of phenazines as cancer chemopreventive agents Computer-based design and synthesis of indenoisoquinolines as retinoid X receptor ligands 	2007–2012
Graduate Researcher, University of Utah Prof. Janis Louie <ul style="list-style-type: none"> Synthesis and characterization of Ni-<i>N</i>-heterocyclic carbene complexes Mechanistic studies of vinylcyclopropane-cyclopentene rearrangement 	2005–2007
Undergraduate Researcher, Brigham Young University Prof. John D. Lamb; Prof. Morris J. Robins <ul style="list-style-type: none"> New methodologies for nucleotide synthesis 	2003–2005

Honors and Awards

Best Work, XXI Argentinean Congress of Physical Chemistry and Inorganic Chemistry; Physical Chemistry of Materials	2019
Early Career Reviewer, National Institute of Health, USA	2018
Milstein Fellowship, Ministry of Science and Technology, Argentina	2018
New Investigator Award, University of Nebraska	2016

Cancer Prevention Fellowship, NCI, R25CA128770, Purdue University	2011
Undergraduate Research Award, Brigham Young University	2005
Summer Undergraduate Research Fellowship, University of Texas – SWMC	2004
Office of Research (ORCA) Award, Brigham Young University	2004 & 2005

Funding

Current

1. Nebraska Center for Molecular Target Discovery and Development. P20-GM121316, \$510,980, NIH-NIGMS. (Lewis, PI; Conda-Sheridan, Co-I). 05/01/2018-04/30/2021
2. Modifying Heterocycles to Treat Gram + and Gram – Bacteria. PRMRP#PR172445, \$200,000, Department of Defense. (Conda-Sheridan, PI). 05/01/2018-10/31/2019
3. The Evolution of Self-Assembled Organic Materials. PRF# 57434-DNI7, \$110,000, American Chemical Society (Conda-Sheridan, PI). 09/01/2017-08/31/2019
4. UNMC Diversity Award. \$100,000 (Conda-Sheridan, PI). 06/01/2019-05/31-2021

Completed

1. Nebraska Bankers Association, Equipment grant (To purchase an Isolera Biotage System), \$15,000 (Conda-Sheridan, PI). 01/01/2018-04/30/2018
2. Towards an Effective Prostate Cancer Targeting Biomaterial. 1R03EB022141-01. \$79,980, NIH-NCI (Conda-Sheridan, PI). 04/01/2016-03/31/2018
3. UNMC Diversity Award. \$100,000 (Conda-Sheridan, PI). 06/01/2015-05/31-2017
5. Developing Sugar Amphiphiles, Novel Bioinspired Nanodrugs. DHHS#2018-17, \$ 50,000, Nebraska Department of Human Health (Conda-Sheridan, PI). 07/01/2017-06/30/2018

Publications (* denotes equal contribution)

Independent career

1. Rodriguez de Almeida, N.; Catazaro, J.; Chhonker, Y.; Murry, D.; Powers, R.; **Conda-Sheridan, M.** Understanding the forces involved in membrane interactions of antibacterial peptides and their influence on biological activity and mechanics. Submitted to *Peptides*.
2. Zaldivar, G.; Vemulapalli, S.; Udumula, V.; **Conda-Sheridan, M.**; Tagliazucchi, M. Self-Assembled Nanostructures of Peptide-Amphiphiles: Charge Regulation by Size Regulation. Submitted to *J. Phys. Chem. C*
3. Rodrigues de Almeida, N.; Han, Y.; Perez, J.; Kirkpatrick, S.; Wang, Y.; **Conda-Sheridan, M.** Design, Synthesis, and Nanostructure-Dependent Antibacterial Activity of Cationic Peptide Amphiphiles. *ACS Appl. Mater. Interfaces*. **2019**, *11*, 2790-2801
4. Wood, N.; Chung, K.; Blocker, A.; Rodriguez de Almeida, N.; **Conda-Sheridan, M.**; Fisher, D.; Ouellette, S. Initial Characterization of the Two ClpP Paralogs of *Chlamydia trachomatis* Suggests Unique Functionality for Each. *J. Bacteriol.* **2018**, JB.00635-18
5. Zaldivar, G.; Samad, M.; **Conda-Sheridan, M.**; Tagliazucchi, M. Self-Assembly of Model Short Triblock Amphiphiles in Dilute Solution. *Soft Matter* **2018**, *14*, 3171-3181
6. Samad, M.; Krishnaiah, M.; Rodriguez de Almeida, N.; **Conda-Sheridan, M.** Facile Protocol for the Synthesis of Self-Assembling Polyamine-based Peptide Amphiphiles (PPAs) and Related Biomaterials. *JoVE*. **2018**, 25.
7. Krishnaiah, M.; Rodrigues de Almeida, N.; Udumula, V.; Song, Z.; Chhonker, Y. S.; Abdelmoaty, M. M.; Aragao do Nascimento, V.; Murry, D. J.; **Conda-Sheridan, M.** Synthesis, biological

evaluation, and metabolic stability of new antibacterial phenazines. *Eur. J. Med. Chem.* **2018**, *143*, 936-947

8. Dias de Oliveira, P.; Rodrigues de Almeida, N.; **Conda-Sheridan, M.**; do Prado Aparecido, R.; Michelettia, A. C.; Pereira Carvalhoc, N. C.; dos Anjos dos Santos, E.; Marques, M. R.; de Arrudae, E. J.; Braz Alcantara, G.; Silva de Oliveira, L. C.; Pires de Lima, D.; Beatriz, A. Ozonolysis of neem oil: Preparation and characterization of potent antibacterial agents against multidrug resistant bacterial strains. *RSC Adv.* **2017**, *7*, 34356-34365
9. Samad, M. B.; Chhonker, Y. S.; Contreras, J. I.; McCarthy, A.; McClanahan, M., Murry, D. J., **Conda-Sheridan, M.** Developing Polyamine-based Peptide Amphiphiles with Tunable Morphology and Physicochemical Properties. *Macromol. Biosci.* **2017**, *17*, 1700096.
10. Basiri, A.; Xiao, M.; Mc Carthy, A.; Dutta, D. Byrereddy, S. N.; **Conda-Sheridan, M.** Design and synthesis of new piperidone grafted acetylcholinesterase inhibitors. *Bioorg. Med. Chem. Lett.* **2017**, *27*, 228– 231
11. Udumula, V*. ; Endres, J. L. ; Harper, C. N.; Jaramillo, L.; Zhong, H.; Bayles, K. W. ; **Conda-Sheridan, M***. A Simple Synthesis of Endophenazine G and Its Analogues and Their Biological Evaluation as anti-methicillin-resistant Staphylococcus aureus agents. *Eur. J. Med. Chem.* **2016**, *128*, 710– 721

Before independent career

12. **Conda-Sheridan, M.***; Lee, S. S.*; Preslar, A. T.; Stupp, S. I. Esterase-Activated Release of Naproxen from Supramolecular Nanofibres. *Chem. Comm.* **2014**, *50*, 13757– 13760
13. **Conda-Sheridan, M.***; Park, E. J.*; Beck, D. E.; Reddy, P. V. N.; Nguyen. T. X.; Hu, B.; Chen, L.; White J. J.; van Breemen, R. B.; Pezzuto, J. M.; Cushman, M. Design, Synthesis, and Biological Evaluation of Indenoisoquinoline Rexinoids with Chemopreventive Potential. *J. Med. Chem.*, **2013**, *56*, 2561–2605
14. **Conda-Sheridan, M.***; Reddy, P. V. N.*; Morrell, A.; Chen, L.; van Breemen, R. B.; Park, E. J.; Kondratyuk, T. P.; Pezzuto, J. M.; Cushman, M. Synthesis and Biological Evaluation of Indenoisoquinolines That Inhibit Both Tyrosyl-DNA Phosphodiesterase I (Tdp1) and Topoisomerase I (Top1). *J. Med. Chem.*, **2013**, *56*, 182–200
15. **Conda-Sheridan, M.***; Chen, L.*; Reddy, P. V. N.; Morrell, A.; van Breemen, R. B.; Park, E. J.; Kondratyuk, T. P.; Pezzuto, J. M.; Cushman, M. Identification, Synthesis, and Biological Evaluation of the Metabolites of 3-Amino-6-(3'-aminopropyl)-5*H*-indeno[1,2-*c*]isoquinoline-5,11-(6*H*)dione (AM6–36), a Promising Rexinoid Lead Compound for the Development of Cancer Chemotherapeutic and Chemopreventive Agents. *J. Med. Chem.*, **2012**, *55*, 5965–5981
16. Nguyen, T. X.; Morrell, A.; **Conda-Sheridan, M.**; MArchand, C.; Agama, K.; Bermingam, A.; Stephen, A. G.; Chergui, A.; Naumova, A.; Fisher, R.; O'Keefe, B. R.; Pommier, Y.; Cushman, M. Synthesis and Biological Evaluation of the First Dual Tyrosyl-DNA Phosphodiesterase I (Tdp1)–Topoisomerase I (Top1) Inhibitors. *J. Med. Chem.*, **2012**, *55*, 4457–4478
17. Park, E. J.; Kiselev, E.; **Conda-Sheridan, M.**; Cushman, M.; Pezzuto, J. M. Induction of Apoptosis by 3-Amino-6-(3-aminopropyl)-5,6-dihydro-5,11-dioxo-11*H*-indeno[1,2-*c*]isoquinoline via Modulation of MAPKs (p38 and Jun *N*-terminal Kinase) and *c*-Myc in HL-60 Human Leukemia Cells. *J. Nat. Prod.*, **2012**, *75*, 378–384
18. Zhang, K. **Conda-Sheridan, M.**; Cooke, S. R.; Louie, J. *N*-Heterocyclic Carbenes Bound to Nickel(II) Complexes and Their Role in Catalysis. *Organometallics*, **2011**, *30*, 2546–2552
19. Park, E.; J.; Kondratyuk, T.P.; Morrell, A.; Kiselev, E.; **Conda-Sheridan, M.**; Cushman, M.; Ahn, S.; Choi, Y.; White, J.J.; van Breemen, R. B.; Pezzuto, J. M. . Induction of Retinoid X Receptor Activity and Consequent Up-regulation of p21^{WAF1/CIP1} by Indenoisoquinolines in MCF7 Cells. *Can. Prev. Res.* **2011**, *4*, 592–607
20. Marler, L.; **Conda-Sheridan, M.**; Cinelli, M.A.; Morrell, A.E.; Cushman, M.; Chen, L.; Huang, K.; Van Breemen, R.; and Pezzuto, J. M. Cancer Chemopreventive Potential of Aromathecins and Phenazines, Novel Natural Product Derivatives. *Anticancer Res.* **2010**, *30*, 4873–4882
21. **Conda-Sheridan, M.**; Marler, L.; Park, E. J.; Kondratyuk, T. P.; Jermihov, K.; Mesecar, A. D.; Pezzuto, J. M.; Asolkar, R. N.; Fenical, W.; Cushman, M. Potential Chemopreventive Agents Based

- on the Structure of the Lead Compound 2-Bromo-1-hydroxyphenazine, Isolated from *Streptomyces* Species, Strain CNS284. *J. Med. Chem.* **2010**, *53*, 8678–8689
22. Wang, S. C.; Troast, D. M.; **Conda-Sheridan, M.**; Zuo, G.; LaGarde, D.; Louie, J.; Tantillo, D. J. Mechanism of the Ni(0)-Catalyzed Vinylcyclopropane–Cyclopentene Rearrangement. *J. Org. Chem.* **2009**, *74*, 7822–7833
 23. Gardner, J. S.; **Conda-Sheridan, M.**; Smith, D. N.; Harrison, R. G.; Lamb, J. D. Anion Binding by a Tetradipicolylamine-Substituted Resorcinarene Cavitand. *Inorg. Chem.* **2005**, *44*, 4295–4300
 24. Nowak, I.; **Conda-Sheridan, M.**; Robins, M. J. Nucleic Acid Related Compounds. 127. Selective N-Deacylation of N,O-Peracylated Nucleosides in Superheated Methanol *J. Org. Chem.* **2005**, *70*, 7455–7458

Patents

1. Cushman, M.; Nguyen, T. X.; **Conda-Sheridan, M.** Synthesis and use of dual tyrosyl-DNA phosphodiesterase I (tdp1)-topoisomerase I (top1) inhibitors. US 2013-13834652. Dec 26, 2013

Book Chapters

1. **Conda-Sheridan, M.** Self-assembling biomaterials as nanocarriers for the targeted delivery of drugs for cancer. Self-assembling Biomaterials: Molecular Design, Characterization and Application in Biology and Medicine. 1st ed. Helena S. Azevedo, Ricardo M. P. da Silva Eds.; Woodhead Publishing, 2018, Ch 23; pp 495–532

Reviews

1. Rodriguez de Almeida, N.; **Conda-Sheridan, M.** A Review of the Molecular Design and Biological Activities of RXR Agonists. *Med. Res. Rev.* **2019**

Scientific Service

1. Reviewer, AAAS, Research Competitiveness program. March, 2019
2. Reviewer, NIH, ZGM1 RCB-6 Study section. November 2018
3. Reviewer, NIH, DMP Study section. June 2018
4. Reviewer, AAAS, Research Competitiveness program. Feb and May, 2018
5. Reviewer, NSF, Division of Materials Research (DMR), BMAT panel. Oct, 2015; Oct, 2016
6. Reviewer, ACS, Petroleum Research Found (PRF), Committee 10. February 2016
7. Judge, Midwest Student Biomedical Research Forum. March, 2016
8. Member Faculty Development Section, AACP, 2016
9. Journal Reviewer for: ACS Applied Materials and Interfaces; ACS Infectious Diseases; Angewandte Chemie International Edition; Anti-Cancer Agents in Medicinal Chemistry; Bioorganic Chemistry; Bioorganic and Medicinal Chemistry; European Journal of Medicinal Chemistry; Heliyon; Journal of Agricultural and Food Chemistry; Journal of the Chemical Society of Pakistan; Letters in Drug Design and Discovery; Nanomedicine: Nanotechnology, Biology, and Medicine; Peptide Science, Small.

Invited Lectures

1. Nanostructures as Antibacterial Agents. Role of Supramolecular Morphology in Biological Action. Georgia State University, April 23, 2019. Host: Binghe Wang
2. Nanostructures as Antibacterial Agents. Role of Supramolecular Morphology in Biological Action. University of Illinois at Chicago, April 3, 2019. Host: Richard Gemeinhart

3. Design, Synthesis, and Evaluation of Amphiphilic Peptides as New Antimicrobial Agents. Wichita State University, October 3, 2018. Host: Dennis Bruns
4. The Development of Small Molecule Antibacterials. DePaul University, September 14, 2018. Host: Charles Rubert Perez
5. Synthesis, Biological Evaluation, and Metabolic Studies of Phenazines, 2018 ACS-National Meeting, August 20, 2018. Host: Kyung Myung
6. Development of Self-Assembling Biomaterials with Biomedical Applications. Center of Investigations in Biosciences (CIBION), Argentina, August 1, 2018. Host: Leonardo Lizarraga
7. Design and Development of Self-Assembling Biomaterials. University of Buenos Aires-INQUIMAE, Argentina, July 30, 2018. Host: Mario Tagliazucchi
8. Design and Development of Self-Assembling Biomaterials. University of San Martin, Argentina, July 27, 2018. Host: Fernanda Cardinal
9. Development of Self-Assembling Biomaterials with Biomedical Applications. University of Chile, Chile, July 4, 2018. Host: Dante Miranda
10. Design and Development of Self-Assembling Biomaterials. University of Sao Paulo-Ribeirao Preto, Brazil, June 23, 2018. Host: Flavio Da Silva Emery
11. Antimicrobial Activity of Amphiphilic Peptides-Composition and Structure. Federal University of Grande Dourados, Brazil, June 20, 2018. Host: Eduardo Arruda
12. Antimicrobial Activity of Amphiphilic Peptides. Federal University of Mato Grosso do Sul, Brazil, June 19, 2018. Host: Adilson Beatriz
13. Small Molecules, Peptides, and Nanostructures; Where Can We find the Next Antibacterial? University of Nebraska at Lincoln, April 10, 2017. Host: LiangChen Du
14. Synthesis and Development of Novel Self-assembling Biomaterials. University of Nebraska at Omaha, October 5, 2015. Host: Andy Zhong

Trained Personnel

- Visiting Scholars.
 - a. Dr. Zhong Cheng Song (2016-2017, CSC Scholar)
 - b. Dani Arakaki (2018-2019. CAPES Scholar)
 - c. Mai Mostafa Gohar (2016-2017, Fulbright scholar)
- Postdoctoral Students.
 - a. Dr. Venkatarreddy Udumula (2015-2019). Next position; Postdoc: Emory
 - b. Dr. Alireza Basiri (2016-2017). Next position; Graduate student, Garrison Lab (UNMC)
 - c. Dr. Maddeboina Krishnaiah (2016-2019). Next position; Postdoc: Duerden lab (UNMC)
 - d. Dr. Nathalia Almeida (2016-2019). Next position; Assistant Professor, UNO
- Graduate Students.
 - a. Mohammed Seleem (2018-present)
 - b. Sridhar Vemulapalli (2018-present)
 - c. Huihua Xing (2018-present)
- Undergraduate Students. Megan McClanahan (2016), Alec McCarthy (2016), Michelle Xiao (2016), Caleb Harper (2016), Jesus Perez (2017-2018), Molly Kohlbek (2017), Alex Wu (2018-2019)
- High School Students. Sidney Kirkpatrick (2016-2017), Mohamad Hazin (2017-2018), Zachary Vacure (2018-2019)

Teaching Experience

Department of Pharmaceutical Sciences, University of Nebraska Medical Center


- Pharmaceutical Sciences II (PHSC 670)
- Medicinal Chemistry I (PHSC 626)
- Pharmaceutical Chemistry (PHSC 852)

- Pharmaceutical Biotechnology (PHSC 520)
- Quantitative Pharmaceutical Analysis (PHSC 845)

The presented information is accurate and current to this date; May 24, 2019

A handwritten signature in black ink, reading "Martin Conda-Sheridan". The signature is written in a cursive style, with "Martin" on the first line, "Conda" on the second line, and "Sheridan" on the third line.

Martin Conda-Sheridan
Assistant Professor
Pharmaceutical Sciences
PDD 3026, 4040 Emile St
986125 University of Nebraska Medical Center
Omaha, NE 68198-6125
402-559-9361



Initial Characterization of the Two ClpP Paralogs of *Chlamydia trachomatis* Suggests Unique Functionality for Each

Nicholas A. Wood,^{a,b} Krystal Y. Chung,^c Amanda M. Blocker,^c Nathalia Rodrigues de Almeida,^d Martin Conda-Sheridan,^d
Derek J. Fisher,^c Scot P. Ouellette^a

^aDepartment of Pathology and Microbiology, College of Medicine, University of Nebraska Medical Center, Omaha, Nebraska, USA

^bDivision of Basic Biomedical Sciences, Sanford School of Medicine, University of South Dakota, Vermillion, South Dakota, USA

^cDepartment of Microbiology, Southern Illinois University Carbondale, Carbondale, Illinois, USA

^dDepartment of Pharmaceutical Sciences, College of Pharmacy, University of Nebraska Medical Center, Omaha, Nebraska, USA

ABSTRACT Members of *Chlamydia* are obligate intracellular bacteria that differentiate between two distinct functional and morphological forms during their developmental cycle, elementary bodies (EBs) and reticulate bodies (RBs). EBs are nondividing small electron-dense forms that infect host cells. RBs are larger noninfectious replicative forms that develop within a membrane-bound vesicle, termed an inclusion. Given the unique properties of each developmental form of this bacterium, we hypothesized that the Clp protease system plays an integral role in proteomic turnover by degrading specific proteins from one developmental form or the other. *Chlamydia* spp. have five uncharacterized *clp* genes, *clpX*, *clpC*, two *clpP* paralogs, and *clpB*. In other bacteria, ClpC and ClpX are ATPases that unfold and feed proteins into the ClpP protease to be degraded, and ClpB is a deagggregase. Here, we focused on characterizing the ClpP paralogs. Transcriptional analyses and immunoblotting determined that these genes are expressed midcycle. Bioinformatic analyses of these proteins identified key residues important for activity. Overexpression of inactive *clpP* mutants in *Chlamydia* spp. suggested independent function of each ClpP paralog. To further probe these differences, we determined interactions between the ClpP proteins using bacterial two-hybrid assays and native gel analysis of recombinant proteins. Homotypic interactions of the ClpP proteins, but not heterotypic interactions between the ClpP paralogs, were detected. Interestingly, protease activity of ClpP2, but not ClpP1, was detected *in vitro*. This activity was stimulated by antibiotics known to activate ClpP, which also blocked chlamydial growth. Our data suggest the chlamydial ClpP paralogs likely serve distinct and critical roles in this important pathogen.

IMPORTANCE *Chlamydia trachomatis* is the leading cause of preventable infectious blindness and of bacterial sexually transmitted infections worldwide. Chlamydiae are developmentally regulated obligate intracellular pathogens that alternate between two functional and morphologic forms, with distinct repertoires of proteins. We hypothesize that protein degradation is a critical aspect to the developmental cycle. A key system involved in protein turnover in bacteria is the Clp protease system. Here, we characterized the two chlamydial ClpP paralogs by examining their expression in *Chlamydia* spp., their ability to oligomerize, and their proteolytic activity. This work will help understand the evolutionarily diverse Clp proteases in the context of intracellular organisms, which may aid in the study of other clinically relevant intracellular bacteria.

KEYWORDS *Chlamydia*, Clp protease, ClpP, differentiation, protein quality control, protein turnover

Citation Wood NA, Chung KY, Blocker AM, Rodrigues de Almeida N, Conda-Sheridan M, Fisher DJ, Ouellette SP. 2019. Initial characterization of the two ClpP paralogs of *Chlamydia trachomatis* suggests unique functionality for each. J Bacteriol 201:e00635-18. <https://doi.org/10.1128/JB.00635-18>.

Editor Ann M. Stock, Rutgers University-Robert Wood Johnson Medical School

Copyright © 2018 American Society for Microbiology. All Rights Reserved.

Address correspondence to Scot P. Ouellette, scot.ouellette@unmc.edu.

Received 16 October 2018

Accepted 24 October 2018

Accepted manuscript posted online 5 November 2018

Published 20 December 2018

Chlamydia trachomatis is one of the most prevalent human sexually transmitted infections and the leading cause of preventable infectious blindness worldwide (<http://www.who.int/en/news-room/fact-sheets/detail/trachoma>). Of particular note are the negative effects associated with untreated *C. trachomatis* infections. Because of the asymptomatic nature of 60 to 80% of cases (1), infection by this organism can lead to complications, such as pelvic inflammatory disease, which can in turn lead to infertility and ectopic pregnancies in women (<https://www.cdc.gov/std/stats16/chlamydia.htm#foot-1>). An infant can also acquire conjunctivitis during birth should the mother be infected, which can result in irreversible blindness if left untreated.

C. trachomatis is an obligate intracellular pathogen with a complex developmental cycle (see reference 2 for a detailed review). These pathogenic bacteria differentiate between two distinct functional and morphological forms over the course of 48 to 72 h, depending on the strain. The electron-dense elementary body (EB) is the infectious but nondividing form that is characterized by its histone-compacted chromosome (3) and cysteine-rich disulfide-cross-linked outer membrane (4). The reticulate body (RB) is the noninfectious and replicating form that has a relaxed chromosome structure and lipid-based cell walls that are sensitive to disruption. The typical sizes of the two forms are $\sim 0.3 \mu\text{m}$ and $\sim 1 \mu\text{m}$, respectively (2). A single EB initiates infection of a host cell by attaching to the plasma membrane and inducing uptake into the cell by type III secreted effectors (5, 6). The EB remains within a host-derived vesicle, which is diverted from the endocytic pathway and differentiates into the much larger RB. The vesicle is rapidly modified into a pathogen-specified parasitic organelle termed an inclusion (7, 8). Proliferation of this RB within the inclusion follows until such time that secondary differentiation occurs, and the RBs begin to condense their genome and cross-link their outer membrane. After a significant amount of EBs have accumulated, they exit the cell for infection of surrounding cells. Proteomic and transcriptional analyses indicate that EBs and RBs have distinct patterns of gene expression and protein repertoires (9–12). Given the striking phenotypic differences between the two developmental forms, we hypothesize that protein turnover plays a key role in differentiation, in addition to general maintenance of bacterial homeostasis during both normal and persistent growth modes (13–15).

Even though chlamydiae exhibit such a complex developmental cycle and evade the host immune system during chronic infections, these bacteria have undergone significant reductive evolution to eliminate unnecessary genes. This in turn suggests that most genes retained by this organism likely serve an important function to bacterial fitness (16). Within its genome, *Chlamydia* spp. encode homologs to four caseinolytic protease (*clp*) genes, *clpC*, *clpX*, *clpP* (*clpP1* and *clpP2*), and *clpB*. ClpB is a putative deaggagase and does not appear to interact directly with other Clp proteins for proteomic turnover (10). ClpC and ClpX proteins are classified as AAA+ (ATPases associated with various cellular activities) unfoldases that serve to linearize target proteins in an ATP-dependent manner (17, 18). ATP binding, but not necessarily hydrolysis, potentiates interactions between a homohexamer of these proteins and a ClpP complex in other organisms (19, 20). ClpP is a serine protease that gives peptidase function to the resultant complex (21). ClpP proteins have been shown to oligomerize into a tetradecameric complex of a stack of two heptamers that can then perform proteolytic function upon interaction with the unfoldase oligomer (22, 23). Binding of the unfoldase protein complexes relaxes and stabilizes the N-terminal region of the ClpP complex, allowing larger substrates into the proteolytic complex.

Multiple pathogenic bacteria possess two *clpP* paralogs, including *Pseudomonas aeruginosa*, *Listeria monocytogenes*, and *Mycobacterium tuberculosis*. The Baker lab characterized the dual ClpP system of *P. aeruginosa* and demonstrated that each system potentially has a distinct function contributing to virulence and fitness of the bacterium (24). While the group studying ClpP1 and ClpP2 in *Mycobacterium* spp. showed heterologous interactions between these paralogs, these genes are cotranscribed, suggesting coupled function (25). The dual ClpP proteases of *Listeria monocytogenes* were shown to form both hetero- and homotypic complexes (26, 27), yet the authors

demonstrated that *L. monocytogenes* ClpP2 likely can function independently of *L. monocytogenes* ClpP1. These studies, taken together with the reductive evolution of the chlamydial genome and the distinct protein repertoires of EBs and RBs, led us to hypothesize that the chlamydial ClpP proteins may serve distinct and critical functions in the physiology of the organism.

To begin investigating the role of the Clp protease system in chlamydial biology, we initiated a series of studies to characterize the ClpP paralogs. All *clp* genes are expressed as RB-specific gene products during the developmental cycle. Bioinformatic and structural modeling analyses indicate that ClpP1 and ClpP2 proteins retain key residues important for function and structure. Interestingly, overexpression of a mutant ClpP1 was detrimental to chlamydial development, whereas a mutant ClpP2 had no observable effect. Overexpression of wild-type ClpP proteins had no effect on the recovery of infectious EBs. To explore the basis of these observations, we performed a series of *in vitro* and *in vivo* assays to determine the oligomerization and protease activity of each paralog. Whereas we observed homo-oligomerization of each ClpP paralog, we did not detect hetero-oligomerization between these proteins. From *in vitro* protease activity assays, we observed proteolytic activity for ClpP2 only. Consistent with this, antibiotics known to activate ClpP proteases stimulated the protease activity of ClpP2 only and blocked chlamydial growth. Combined, our data suggest that ClpP1 activity may be tightly regulated. We conclude that each chlamydial ClpP protease serves a unique and independent role, either in differentiation or more conserved physiological processes.

RESULTS

The *clp* genes are expressed as RB-specific genes. We hypothesize, based on the arrangement of the genes in the chromosome, that ClpC interacts with ClpP1 and that ClpX interacts with ClpP2. This does not preclude each individual component from acting independently and is not mutually exclusive to our hypothesis. We based our prediction of ClpP2X interaction due to the juxtaposition of the two genes within the same operon (Fig. 1A). We then reasoned that ClpP1 would serve as the proteolytic subunit that would interact with ClpC, as the two are encoded independently of each other in separate genomic contexts (Fig. 1A). Because chlamydiae are developmentally regulated bacteria, gene expression can differ from one developmental form to the other. Gene expression in *Chlamydia* spp. can be broadly categorized into three different stages, early, mid-, and late-developmental cycle genes (28). Early cycle genes are involved in initial differentiation from EB to RB and establishment of the nascent inclusion. Midcycle genes are RB specific and typically play a role in growth and division of the RBs, as well as in inclusion modification. Late-cycle genes function in differentiation from an RB to an EB or serve an important function in the secondary infection of a host cell. The specificity of a transcript to a particular point of the developmental cycle can give insight into the possible function of the encoded protein. To determine when during the developmental cycle the *clp* genes are transcribed, we measured the transcription of each gene over a time course of infection. Nucleic acid samples were collected for analysis at various time points of infection using wild-type *C. trachomatis* L2. Our data indicate that the *clp* genes analyzed are transcribed in a pattern consistent with midcycle RB-specific function since the transcript levels peak after primary differentiation has occurred and a population of RBs has been established (i.e., 16 hours postinfection [hpi]) (Fig. 1B to E).

In parallel, we analyzed lysates from infected cells using primary antibodies generated against the Clp proteins. Given the high level of homology between the *Pseudomonas aeruginosa* ClpP1 and *C. trachomatis* ClpP2 (see Fig. 2), we speculated that a polyclonal antibody developed against *P. aeruginosa* ClpP1 (a kind gift of T. Baker, MIT) would detect *C. trachomatis* ClpP2 by Western blot analysis. *C. trachomatis* ClpP2 was detected from infected cell lysates starting at 24 h postinfection (hpi) using the polyclonal anti-*P. aeruginosa* ClpP1 antibody (Fig. 1C). Given the relatively low levels of ClpP2 compared to the major outer membrane protein (MOMP) (Fig. 1F), we cannot conclude that ClpP2 is not present at earlier times or that an antibody specific to




FIG 1 The *clp* genes are expressed during RB growth. (A) Gene maps of the *clp* genes in the *Chlamydia trachomatis* genome. Gene numbers are in numerical order from left to right and reflect the serovar D numbering scheme from a study by Stephens et al. (16). The *clp* genes are circled. The *clpP2* gene is *ct706*. (B to E) Temporal expression of the *clp* genes. Quantitative reverse transcription-PCR (RT-qPCR) analysis of the *clp* genes from two independent time course experiments of a *C. trachomatis* serovar L2 infection of HEp2 cells was performed. Total RNA and DNA were collected at the indicated times postinfection and processed as described in Materials and Methods. Equivalent amounts of cDNA were used for each assay and analyzed in triplicate. Results are reported as a ratio of cDNA to genomic DNA (gDNA). Standard deviations for each were typically less than 10% of the sample. Note that some transcripts were not detectable at 1 hpi. Western blotting was performed on whole-cell lysates of total protein from a time course of *Chlamydia* sp.-infected cells, separated by SDS-PAGE, and transferred to a nitrocellulose membrane for blotting. All four of the genes analyzed appear to be expressed mid-developmental cycle. (F) Major outer membrane protein (MOMP) was blotted as a control for chlamydial development over the course of infection. Ab, antibody.

chlamydial ClpP2 would be more sensitive to detect such lower levels. The polyclonal antibody developed against *P. aeruginosa* ClpP2 did not react with chlamydial lysates or recombinant *C. trachomatis* ClpP1 or ClpP2 (see Fig. S1 in the supplemental material). We obtained additional antibodies raised against chlamydial ClpP1, ClpX, and ClpC (a kind gift of G. Zhong, UTHSC) and used these antibodies to detect their targets (validated in Fig. S1). We observed patterns of expression for these proteins similar to




FIG 2 Bioinformatics analyses suggest that both chlamydial ClpP paralogs are functional proteases (A). Pairwise alignments were performed using NCBI BLAST (default settings) and presented as percent identity/percent similarity/percent coverage. Multiple-sequence alignment was performed using Clustal Omega with default settings and presented using Jalview version 2. Organisms included are *C. trachomatis* (Ctr), *E. coli* (Ec), *B. subtilis* (Bs), *M. tuberculosis* (Mtb), and *P. aeruginosa* (Pa). Conserved residues are highlighted in various shades of blue depending on conservation strength across species, with the catalytic triad, oligomer interface, and hydrophobic docking region colored as indicated in the key. Residues in which ClpP1 has a radically different substitution compared to other ClpP proteins are denoted by Ω. Residues involved in activation conformational changes are denoted by Ψ (33). (B and C) Predicted 3D structures acquired from Phyre² were aligned and colored in Chimera (UCSF). (B) 3D structural alignment of *C. trachomatis* ClpP1, *C. trachomatis* ClpP2, and *E. coli* ClpP (peptide colors as shown in multiple-sequence alignment). Active-site residues are circled in red. (C) Space-filling model of predicted 3D structures. “Rear” is a 180° rotation around the y axis to show the surface of the protein not shown in the “Front” image.

those for ClpP2, although faint bands for ClpX and ClpC were observed at 16 hpi (Fig. 1B, D, and E). Clp protein levels mirror the transcripts and are detected from mid-developmental cycle for the remainder of the infection. These patterns are distinct to those of canonical early or late cycle genes, such as *euo* or *omcB* (29–31). Operon status seems likely for *clpP2* and *clpX* given that *clpX* so closely mirrors *clpP2*, with slightly lower transcript abundance. Overall, the expression data indicate that the Clp components are expressed primarily in the RB phase of growth and division. This does not,

however, preclude these proteins from having functions at other times during the developmental cycle.

Bioinformatics analyses identify key residues important for structure and function of each chlamydial ClpP paralog. We hypothesized that each ClpP paralog of *C. trachomatis* serves distinct functions in the biology and pathogenesis of this unique bacterium, despite their similarity in expression patterns. To further test this hypothesis, we performed a series of bioinformatics analyses. We began by looking at pairwise alignments of the chlamydial ClpP proteins against each other and against ClpP homologs from other bacteria (Fig. 2A). Interestingly, each chlamydial ClpP shared more homology to ClpP of *Escherichia coli*, at 44% and 55% identity, with E values of 4×10^{-51} and 2×10^{-83} , respectively, and to other ClpP homologs than to its paralog. This observation was supported by the ability of the anti-*P. aeruginosa* ClpP1 antibody to recognize *C. trachomatis* ClpP2 but not *C. trachomatis* ClpP1 (Fig. 1C). The sequence identity between *C. trachomatis* ClpP1 and *C. trachomatis* ClpP2 is 39%, with an E value of 10^{-44} . Similarly, the two ClpP paralogs of *P. aeruginosa* share low similarity to each other compared to other ClpP homologs via protein alignment (data not shown), and each serves a distinct function in *P. aeruginosa* (24). Therefore, these observations support the likelihood that the chlamydial ClpP paralogs have distinct roles.

A closer analysis of the chlamydial ClpP paralogs provides further evidence for a unique functionality of each protein. A 3-dimensional-predicted structure alignment of *C. trachomatis* ClpP1 and ClpP2 to *E. coli* ClpP indicates that the structural architecture would allow for homo-oligomer formation and interaction with unfoldases (Fig. 2B), though distinct differences in the oligomer interface may prevent hetero-oligomerization (32). Additional variation in structure is mostly limited to the N and C termini; however, the catalytic triad active site aligns well for all ClpP homologs analyzed (Fig. 2B and C). Also unique to chlamydial ClpP1 are distinct differences at residues that align to amino acids critical to activation in other bacteria. An alanine at position 37 of *C. trachomatis* ClpP1 may result in a conformational difference in the P1 preactivation complex that precludes P1/P2 interaction (33), which may act as a layer of regulation. Further supporting differential regulation is the lack of an aromatic amino acid at position 57 of ClpP1 that is relatively well conserved in other ClpP homologs, suggesting that *C. trachomatis* ClpP1 enters the "open" conformation differently than *C. trachomatis* ClpP2. Given the conserved catalytic residues and the structural similarity of the *C. trachomatis* ClpP proteins to homologs from a diverse set of bacteria, we conclude that the chlamydial ClpP proteins are *bona fide* proteases. However, the predicted structural differences at the termini of the protein and in other key residues suggest that the chlamydial ClpP proteins (i) do not interact with each other and (ii) have specialized functions.

Overexpression of only inactive ClpP1 negatively affects *C. trachomatis*. Leveraging recent advances in chlamydial genetics, we next determined the effect of overexpression of ClpP proteins in *C. trachomatis*. We designed and constructed plasmids carrying wild type or inactive mutants of each *clpP* paralog, fused to a 6×His tag, under the control of an anhydrotetracycline (aTc)-inducible promoter (34). We successfully transformed *C. trachomatis* with plasmids encoding either the ClpP1(S92A) or ClpP2(S98A) active-site serine mutant known to abolish protease activity (Fig. 2B) (35), in addition to plasmids encoding either wild-type ClpP protein. To assess the effect of overexpression of both the wild-type and the inactive mutant ClpP proteins, HEp2 cells were infected with each transformant, and expression was induced at 10 hpi with 10 nM aTc. Fourteen-hour pulses were utilized to determine inclusion morphology at 24 hpi. The use of aTc at 10 nM did not alter wild-type chlamydial inclusion growth (Fig. S2) (34). At that time point, the localization of the ClpP proteins was within the bacterial cytosol. Overexpression of mutant ClpP1 resulted in noticeably smaller inclusion sizes after 14 h of induction (Fig. 3A), whereas overexpression of inactive ClpP2 had no demonstrable effect (Fig. 3B). Of note is that neither of the wild-type chlamydial ClpP proteins had any apparent negative impact. Further analysis of recoverable inclusion-




FIG 3 Overexpression of wild-type or inactive ClpP proteins has varied effects on *Chlamydia* species. *C. trachomatis* serovar L2 was transformed with aTc-inducible shuttle vectors encoding either wild-type or active-site mutants of each ClpP paralog with a 6×His tag at the C terminus. HEp2 cells were infected with each transformant, and expression was induced at 10 h postinfection (hpi). (A) ClpP1 wild-type and S92A mutant overexpression assay. Overexpression of inactive ClpP1 has a negative impact on the bacteria. (B) ClpP2 wild-type and S98A mutant overexpression assay. Parameters were the same as those described above. Overexpression does not appear to negatively affect *Chlamydia* species. Samples were stained for major outer membrane protein (MOMP; green), 6×His-tagged ClpP protein of interest (red), and DNA (blue). Representative images of three independent experiments are presented. Scale bars are equal to 10 μ m. Images were acquired on a Zeiss LSM 800 laser scanning confocal microscope with a 60× objective and a 3× digital magnification. (C) Inclusion-forming unit (IFU) assay measuring the effect of increasing levels of ClpP protein induction on chlamydial growth. Values are averages of the results from three independent experiments and are reported as a percentage of the respective uninduced sample. *, $P < 0.05$; N.S., not significant.

forming units (IFUs) confirmed the observed reduction in chlamydial viability following ClpP1(S92A) overexpression, with a severe decrease in IFU recovery following a 14-h pulse with the aTc inducer (Fig. 3C). Conversely, ClpP2(S98A) or wild-type protein overexpression has no statistical and likely no biologically significant impact on development. From these data, we conclude that overexpression of ClpP1(S92A) is detrimental to chlamydiae. In support of this, we were unable to isolate a clonal population of purified ClpP1(S92A) transformants, as we routinely observed small bacterial populations susceptible to antibiotic selection even after multiple passages. This observation indicates that leaky expression may drive plasmid loss, as has been observed in other chlamydial transformation systems (36, 37).

ClpP paralogs demonstrate homotypic, but not heterotypic, interactions. To better understand the function of each ClpP paralog and why overexpression of ClpP1(S92A) but not ClpP2(S98A) or wild-type protein was detrimental to *Chlamydia* spp., we initiated a series of *in vivo* and *in vitro* biochemical assays to characterize the properties of the ClpP proteins. Extensive evidence exists from other bacterial systems to indicate that ClpP forms a tetradecameric complex composed of two heptameric rings (19–23, 38, 39). To determine whether the chlamydial ClpP paralogs formed homo- and/or hetero-oligomers, we first employed the bacterial adenylate cyclase-




FIG 4 The chlamydial ClpP paralogs self-associate but do not form hetero-oligomeric complexes. (A) Bacterial adenylyl cyclase-based two-hybrid assay of homotypic interactions of *C. trachomatis* (Ctr) ClpP1 and ClpP2. The indicated constructs encoding each *clpP* paralog fused to the T18 or T25 fragment of the Cya toxin of *B. pertussis* were cotransformed into *E. coli* DHT1 Δ cya and plated on minimal medium containing X-Gal. Interactions between proteins results in the formation of blue colonies. Representative images of results from at least three independent experiments are shown, along with positive (Zip/Zip) and negative (T25 empty vector versus T18-Zip) controls. Photos set to grayscale. (B) β -Galactosidase assay results from experiments performed as described for panel A. The x axis indicates the test conditions for proteins fused to the T25 or T18, as indicated. Interactions are considered positive when at least five times the activity of the negative control is measured. Only homotypic interactions were positive in these assays. (C) Test of ClpP oligomerization by native PAGE. Five-microgram samples were run on 4 to 20% native PAGE gels and stained with Coomassie blue for protein detection. Representative results from at least three experiments with independent protein purifications are shown. The *C. trachomatis* ClpP1 methionine mutant (M6L-M7I) was run in a separate lane, and the contrast was uniformly adjusted to help with band visualization. Native molecular weight markers are shown to the left of the gel. *E. coli* (Ec) ClpP is included as a positive control on the far right of the gel. (D) Test of hetero-oligomerization between *C. trachomatis* ClpP1 and *C. trachomatis* ClpP2. Each recombinant protein was incubated together prior to electrophoresis. The gel has been cropped and enlarged to aid in detecting P1 and P2 hetero-oligomers, which appear to be absent, consistent with panel B results. The predicted heptamer/tetradecamer sizes in kilodaltons are as follows: *C. trachomatis* ClpP1, 154/308; *C. trachomatis* ClpP2 161/322; and *E. coli* ClpP, 168/336.

based two-hybrid (BACTH) system to detect protein-protein interactions. This *in vivo* assay is based on the reconstitution of adenylyl cyclase activity when two functional fragments of Cya from *Bordetella pertussis* are brought into close proximity by interacting proteins (40). Interactions can be qualitatively determined on 5-bromo-4-chloro-3-indolyl- β -D-galactopyranoside (X-Gal) plates and quantified by β -galactosidase activity. Using the BACTH system, we observed homo-oligomerization of each ClpP paralog but failed to detect interactions between ClpP1 and ClpP2 (Fig. 4A and B). Importantly, the active-site mutants also interacted with each other and the wild-type proteins, indicating that this mutation did not interfere with homo-oligomerization (Fig. 4B). These data are consistent with the predicted structural and sequence differences noted (Fig. 2B and C).

As the BACTH system cannot indicate oligomerization state, we next purified recombinant chlamydial ClpP1 and ClpP2 (22 and 23 kDa, respectively), including the active-site mutants, and analyzed their migration by native PAGE. As a positive control, we also purified *E. coli* ClpP (24 kDa). Each of the recombinant chlamydial proteins clearly formed a heptamer with a fainter slower migrating band, indicating potential




FIG 5 Chlamydial ClpP2, but not ClpP1, has ATPase-independent protease activity. *In vitro* protease activity of the *C. trachomatis* ClpP proteins versus a peptide substrate is shown. ClpP samples (1 μM monomer) were incubated with the fluorometric peptide Suc-Luc-Tyr-AMC, and fluorescence was analyzed over time. (A) Relative activity is shown for each protein run with or without the sodium citrate buffer. The use of sodium citrate buffer is indicated as “Sod-Cit.” Loss of activity is observed for the *C. trachomatis* ClpP2 catalytic serine mutant. (B) *E. coli* ClpP was used as a positive control. Experiments were run a minimum of three times, and baseline assay values obtained with buffer alone were subtracted from each sample. Average values are reported with standard error.

tetradecamer forms (Fig. 4C). The *E. coli* ClpP, in contrast, migrated primarily as a tetradecamer with a less intense band at the predicted size of a heptamer. In purifying *C. trachomatis* ClpP1, we noticed the presence of a doublet band (Fig. S3). However, the N terminus encodes two additional methionine residues at positions 6 and 7; thus, the smaller product may have resulted from an alternative start site when expressed in *E. coli*. Mass spectrometry analysis of the N terminus of each band supported this conclusion (Fig. S3). Note that the BACTH constructs relied on N-terminal fusions such that the alternative start site of ClpP1 would not be relevant. To ensure that only the larger full-length recombinant ClpP1 product was produced, we mutated the methionine residues to leucine and isoleucine. This recombinant ClpP1 (M6L-M7I) also migrated predominantly as a heptamer in the native PAGE assay (Fig. 4C). Therefore, we conclude that the smaller product did not alter the oligomerization state of the protein.

Both our bioinformatics predictions and the BACTH data indicated that ClpP1 and ClpP2 do not interact. To further test this, we mixed each recombinant protein in equimolar amounts and analyzed their oligomerization state by native PAGE. In support of our early observations, we did not observe heteromers of each ClpP paralog, as each protein ran as distinct heptamers, with no intermediate bands indicative of mixing of the monomers (Fig. 4D). However, we cannot exclude the possibility that the *in vitro* conditions preclude an interaction between these components or that these paralogs interact *in vivo*. Nevertheless, given the differences in predicted structures at the termini of each ClpP paralog (Fig. 2) and the different interaction data presented, the parsimonious interpretation is a model wherein each protease complex functions separately.

Chlamydial ClpP1 and ClpP2 vary in protease activity *in vitro*. To determine the functionality of the protease complexes, we used the recombinant ClpP proteins to assess their ability to degrade the small fluorogenic compound Suc-LY-AMC. The degradation of this compound by other bacterial ClpP enzymes does not rely on ClpP activation (41); thus, we could probe the basal protease activity of the ClpP paralogs. While ClpP2 degraded the substrate under our given assay conditions, ClpP1 activity could not be detected (Fig. 5A). This result for ClpP1 was not due to the presence of the alternative start site product, since the M6L-M7I mutant displayed no activity in this assay. We also observed enhanced protease activity for ClpP2 in a sodium citrate buffer, as noted by others (42), but this buffer did not stimulate ClpP1 activity. The fact that ClpP1 lacks the ability to degrade Suc-LY-AMC suggests that the N-terminal region of

the complex (Fig. 2) may block the entry of even this small reporter substrate into the active site. Importantly, the activity of the ClpP2 protease was abolished by the active-site serine mutation S98A (Fig. 5A). As a positive control, we also tested the activity of the *E. coli* ClpP complex under our assay conditions and observed degradation of the Suc-LY-AMP compound that was increased by sodium citrate (Fig. 5B). Thus, in spite of the activity of *C. trachomatis* ClpP2, it displayed significantly less proteolytic capacity *in vitro* than the *E. coli* ClpP. The apparent preference of heptameric formation by both chlamydial ClpP1 and ClpP2 might explain the reduced activity compared to the *E. coli* ClpP, which preferentially formed tetradecamers *in vitro*. These observed differences may suggest that either the assay conditions are not optimal or that chlamydiae tightly regulate the activity of their ClpP complexes.

ClpP-activating antibiotics stimulate protease activity of ClpP2, but not ClpP1, and block chlamydial growth. Recently, a novel class of antibiotics that target ClpP have been developed (43). Acyl-carrier-protein (ACP) and acyldepsipeptide (ADEP) derivatives activate ClpP by eliminating or reducing its need for ATPase binding. The unregulated proteolysis that results has been demonstrated to eliminate persister bacteria (44). We used these compounds to determine whether the activated chlamydial ClpP proteases could degrade a more complex substrate, casein. As noted with the Suc-LY-AMP substrate, ClpP1 failed to degrade casein in the presence of any of the ACP1 derivatives (Fig. 6A). In contrast, the ACP1 compounds stimulated ClpP2 to degrade casein (Fig. 6B), albeit with some detectable substrate remaining at the end of the assay. As before, the *E. coli* ClpP was more efficient in degrading the substrate, with little to no casein detectable (Fig. 6C) (45). ClpP2 was thus able to, in the presence of these drugs that relax the N termini of the complex, degrade larger substrates with intrinsically disordered regions (i.e., casein). The inability to detect proteolytic activity of ClpP1 again suggests that the N terminus of ClpP1 may act as a regulatory block consistent with the differences we observed in our bioinformatics analysis (Fig. 2). Also consistent with the difference in activation is the lack of an aromatic amino acid at residue 57 of *C. trachomatis* ClpP1. This particular residue of the hydrophobic pocket has recently been shown to be instrumental in ADEP-induced dysregulation of proteolytic activity, which supports a model where chlamydial ClpP1 is unaffected by activating drugs (33). However, we cannot exclude that we have not identified the optimal conditions necessary to demonstrate the enzyme activity of wild-type ClpP1.

As we were able to demonstrate the ability of the ACP1 compounds to activate *C. trachomatis* ClpP2, we next sought to test the effect of these compounds on *Chlamydia* species. To ensure that any effect on the bacteria was not due to host cell death, we first tested the cell viability of infected ACP-treated HEp2 cells. Indeed, we noted limited loss (~10%) in host cell viability for both 25 and 50 μ g/ml concentrations following 16 h of drug treatment (Fig. 6D), which reinforces the idea that any loss of bacterial viability would not be due to a reduction in host cell viability. The ACP drugs all showed a remarkable impact on *Chlamydia* spp. at both concentrations tested when added at 8 hpi, and samples were harvested at 24 hpi (Fig. 6E). The lower drug concentration resulted in a 50-fold reduction in recoverable EBs, whereas the higher concentration led to almost complete abrogation of chlamydial viability. Given the effects of the ACP compounds on ClpP protease activity *in vitro*, these data suggest that uncoupling of ClpP2 activity from its cognate ATPase strongly inhibits bacterial growth.

DISCUSSION

The Clp protease system has been extensively characterized in *E. coli* and *Bacillus subtilis*, and its importance in the growth and virulence of various pathogens (opportunistic or not) has been examined (see reference 21 for a review). Since the discovery of the ClpP protease (46), interaction studies demonstrated that the ClpP proteins typically form a tetradecameric stack of two heptamers (47). The serine active sites are buried within these barrel-like structures (48). ClpP hydrolysis of large protein substrates is increasingly stimulated in the presence of AAA+ ATPase binding (49). However, complexed ClpP alone processes small substrates of up to 30 amino acids




FIG 6 ClpP2, but not ClpP1, activity is stimulated by the antibiotic ACP1, which is detrimental to chlamydial growth. (A to C) Casein (1 µg) was incubated with 1 µM the respective ClpP at 37°C for 3 h with or without the ACP compounds (used at 500 µM). Reactions were halted by mixing samples with Laemmli buffer, followed by boiling. Samples were run on 12% SDS-PAGE and stained with Coomassie blue. Molecular weight markers are shown to the left of each gel. Representative gels are shown; at least three experiments were performed for each protein. (D) Cell viability of ACP-treated cells was analyzed with resazurin assays. Values are reported as a percentage of the vehicle control and are representative of three independent experiments. (E) Reinfection models of ACP drug-treated cells reported on a log₁₀ scale. Student's two-tailed *t* test was used to compare each parameter to the vehicle control (***, *P* < 0.0001). (D and E) HEp2 cells were infected with *C. trachomatis* serovar L2, and the ACP1 compounds or DMSO only was added to the infected cultures at 8 h postinfection (hpi). At 24 hpi, cell viability was assessed for panel D or infected cells were collected to reinfect fresh monolayers to determine the recovery of inclusion-forming units (IFUs) as described in Materials and Methods for panel E.

regardless of the presence of ATP, suggesting that active-site availability and complex accessibility are the two main mechanisms regulating ClpP activity (50). Substrates that enter this complex by either ATPase-mediated or ATPase-independent means are hydrolyzed into short peptides of 6 to 8 amino acids with some degree of amino acid specificity (42, 51). While not unprecedented, the presence of two *clpP* paralogs in a bacterial chromosome is unusual. In *P. aeruginosa*, another bacterium encoding dual ClpP proteases, the two isoforms have not been shown to interact under any test condition, and the different transcriptional profiles and differential effects on virulence factor production indicate that these paralogs likely have distinct roles in *P. aeruginosa* (24). Conversely, the two ClpP proteins of *M. tuberculosis* and *L. monocytogenes* heterologously interact as two homotypic heptamers, which facilitates an increase in function (25, 27, 52). The activation of one homotypic ClpP heptamer activates the heptamer of the other isoform in *M. tuberculosis*, providing a novel mechanism for activation (39). Of note is that *L. monocytogenes* ClpP2 may also form a completely homotypic tetradecamer of one ClpP paralog (26). Again, the Clp proteolytic subunits play an integral role in virulence factor regulation, in addition to enhancement of bacterial survival during intracellular growth (53). Taken together, these studies dem-

onstrate the diverse function of dual ClpP peptidase systems in the pathogenesis and growth of various bacteria.

The work presented here to characterize the ClpP paralogs is the first to explore the function and role of the Clp system in *C. trachomatis*. Our results suggest that the two ClpP proteins likely serve distinct roles in chlamydial physiology and, we hypothesize, in the complex developmental cycle of this organism. We utilized bioinformatics techniques as an initial approach to investigate the potential function of the ClpP proteins. We observed significant similarity of the chlamydial ClpP paralogs to ClpP homologs of more studied organisms, such as *E. coli*. In support of this, most of the hallmark conserved residues, including the active-site triad, are present in the chlamydial ClpP paralogs. Both ClpP1 and ClpP2 have hydrophobic residues aligned with those of other bacterial ClpP proteins, suggesting the presence of AAA+ unfoldase protein docking sites (54). Indeed, chlamydial ClpC and ClpX encode the evolutionarily retained IGF/L loop motifs that facilitate interaction with the ClpP tetradecameric complex (N. Wood and S. Ouellette, unpublished data) (39). In spite of the similarities between the ClpP paralogs, there are also notable differences. The C termini of both chlamydial ClpP proteins contain two residues that comprise the hydrophobic pocket (45, 55), but the alignment shows the presence of charged residues (D15, K40, K41, and D66) in ClpP1, while the conserved residues appear to be uncharged. In addition, ClpP1 lacks a highly conserved tyrosine residue (D15), a conserved glutamine (A36), and a conserved aromatic residue (V57), all of which contribute to canonical activation and tetradecamer chamber access for other homologs (33). Ongoing studies are investigating these residues in addition to others that are involved in complex activation. Of note is the predicted alpha helix at the N terminus of ClpP1 and the C terminus of ClpP2, which may contribute to some form of steric hindrance to prevent interaction between ClpP1 and ClpP2 (56). Indeed, we did not detect an interaction between ClpP1 and ClpP2 using both *in vivo* and *in vitro* techniques. Rather, we detected only homo-oligomers. While our *in vitro* assays have failed to show P1/P2 complex formation, we cannot rule out the possibility of protein modification promoting heteromers *in vivo*. Further studies examining the role of the N and C termini will be conducted to determine whether or not they play a role in complex formation and/or specificity.

Given the role of the N-terminal regions in regulation of the ClpP protease via reduced access into the proteolytic complex (57), the hypothesis of a difference in interaction or regulation of the ClpP complexes in *C. trachomatis* is reasonable based on the data presented here. We detected ClpP2 protease activity against both a small oligopeptide substrate and the more complex casein substrate. However, we did not detect proteolytic activity of ClpP1 *in vitro*, even in the presence of well-characterized drugs that activate ClpP complexes in the absence of an ATPase, which agrees with an important and highly regulated role for ClpP1 in *C. trachomatis*. The structural conservation and presence of the catalytic active site make it unlikely that ClpP1 is a catalytically inactive protease. Rather, some form of modification or conformational change in structure, possibly chaperone or adaptor mediated, may be necessary to promote full complex formation and activity both *in vitro* and *in vivo*. In this model, an unknown regulatory factor may modulate ClpP1 activity. In a manner consistent with our bioinformatics data, ClpP1 may be activated noncanonically, as the mechanism needed to open the channel at the V57 residue is likely different than those targeting the aromatic amino acids present in other homologs. We are investigating this and other possibilities.

Our data lead us to hypothesize that each ClpP protein in *Chlamydia* spp. forms a separate protease complex and, therefore, serves a different function. Whether each ClpP interacts specifically with ClpX or ClpC remains to be determined. However, the genomic proximity of ClpP2 to ClpX suggests a likely interaction with ClpX by sequestration immediately following translation; thus, we speculate that ClpP1 likely interacts preferentially with ClpC. Our quantitative PCR (qPCR) and Western blot data suggest that the ClpX-encoding gene follows the ClpP2-encoding gene in an operon, further supporting coupled function and an *in vivo* complex of ClpP2 and ClpX oligomers.

Complex formation is under investigation as to what role each complex has *in vivo*. It is also possible that ClpP tetradecamers function independently *in vivo* in a house-keeping role to degrade small oligopeptides resulting from the degradation of larger proteins and/or import from the host cell. Chlamydiae encode a large repertoire of oligopeptide transporters, and the short peptide substrates are an important source of nutrients, particularly early during infection (58).

We were able to transform *C. trachomatis* with plasmids encoding either wild-type or mutant ClpP1 or ClpP2. Overexpression of either wild-type protein had seemingly little negative effect on growth and morphology, which strengthens evidence of a scenario in which these proteins are tightly regulated and exhibit little function without a cognate ATPase. The tolerance of *C. trachomatis* to wild-type ClpP1 and ClpP2 overexpression suggests that this system resists AAA+ ATPase saturation with an overabundance of either proteolytic subunit. Given the reduced tendency for either ClpP to form a tetradecamer, excess ClpP1 or ClpP2 beyond what is needed for homeostasis may also remain in a functionally inactive heptameric form unless recruited by an unfoldase. Interestingly, overexpression of the inactive ClpP mutants in *Chlamydia* spp. resulted in differential effects on chlamydial growth and morphology. ClpP2(S98A) has, even upon the highest level of induction, little negative effect on inclusion morphology. The incorporation of inactive forms of ClpP2 (activity loss confirmed *in vitro*; Fig. 5B) into the tetradecameric oligomer is not necessarily harmful to *C. trachomatis*. The ability of ClpP2 to degrade a small peptide reporter (Fig. 5A) is congruent with a model where an unfoldase-independent ClpP2 tetradecamer targets and degrades imported peptides. Given that overexpression of inactive ClpP2 seems to have limited negative impact on chlamydial development, an inactive ClpP2 oligomer may bind small peptides, preventing extensive targeting of other more vital substrates and negating any dominant negative effect. Conversely, overexpression of ClpP1(S92A) and its incorporation into the endogenous ClpP1 proteolytic machinery have a clear negative impact on *C. trachomatis*. Because overexpression of wild-type ClpP1 has no obvious negative effect, the fact that inactive ClpP1 overexpression reduces chlamydial viability may mean that fully functional operation of ClpP1 is essential to the bacteria. The adverse effect observed may also suggest that ClpP1 has a limited reserve of unique regulators that we have not yet identified and that production of an inactive ClpP1 complex binds these regulators and reduces function to the point of harm to the bacteria. We observed that the mutant ClpP proteins interacted with the wild-type proteins in the BACTH assay (Fig. 4B), suggesting the potential of the inactive proteins to form complexes with the endogenous proteins. Overall, these data suggest that, should each mutant protein oligomerize with endogenous wild-type protein *in vivo*, subunit poisoning of the ClpP1 complex is deleterious to chlamydiae, whereas the ClpP2 complex is more tolerant.

We hypothesize that proteolytic Clp subunit regulation by a chaperone protein is vital to chlamydial survival. Based on our studies with the ACP1 antibiotics, our assays showed that ClpP2 acts in a manner similar to other well-characterized ClpP proteases when artificially activated by these compounds (Fig. 6A and C). Consequently, treatment of *Chlamydia*-infected cells with ACP1 (or one of its derivatives) significantly and drastically reduced chlamydial growth (Fig. 6E), which we speculate is due to the effects on ClpP2 function. Whether the negative effect stems from dysregulation of ClpP2 leading to uncontrolled proteolysis, which is supported by the *in vitro* degradation of casein, or from blocking of ClpP2/AAA+ ATPase complex formation, resulting in the inability to degrade larger substrates not accessible to ClpP2 alone, is under investigation. In spite of the inability of ClpP2(S98A) overexpression to significantly impact chlamydial growth, the antibiotics data suggest that a disruption of ClpP2 via dysregulation of activity is overwhelmingly negative to chlamydial development. However, we cannot exclude a possible effect of these antibiotics on ClpP1 *in vivo*. Clearly, overexpression of ClpP1(S92A) was deleterious to chlamydial growth; thus, each ClpP paralog is essential to normal growth and development.

We have shown here an initial characterization of the chlamydial Clp system

focusing on the ClpP protease components. Overall, the sensitivity of the organisms to perturbations in ClpP activity suggests a critical function for these paralogs in the maintenance of chlamydial physiology. We speculate that these systems will also play an integral role in differentiation and, possibly, persistence (59, 60), which may provide a mechanism that could be leveraged to block growth or eliminate persister cells (44). Further characterization of the chlamydial Clp system could facilitate the development of targeted therapeutics for the treatment of *C. trachomatis* infection, thereby lowering dependence on broad-spectrum antibiotics. Ongoing efforts are investigating this hypothesis as well as the function of the AAA+ unfoldases.

MATERIALS AND METHODS

Strains and cell culture. The human epithelial cell line HEp2 was utilized in the transcriptional and antibiotic studies and was routinely cultivated and passaged in Iscove's modified Dulbecco's medium (IMDM; Gibco/Thermo Fisher; Waltham, MA) and 10% fetal bovine serum (FBS; Sigma, St. Louis, MO). McCoy mouse fibroblasts were used for the purpose of chlamydial transformation, and human epithelial HeLa cells were used for plaque purification of the resulting chlamydial transformants, as well as for protein isolation and assessment of ClpP2 expression. All of these cell lines were passaged routinely in Dulbecco's modified Eagle's medium (DMEM; Gibco/Thermo Fisher). Density gradient-purified *Chlamydia trachomatis* L2/434/Bu (ATCC VR902B) EBs were used for the antibiotic studies. *C. trachomatis* serovar L2 EBs (25667R) naturally lacking the endogenous plasmid were prepared and used for transformation (see reference 61).

Transcript analysis using quantitative reverse transcription-PCR. HEp2 cells seeded in 6-well plates were infected at a multiplicity of infection of 1 with *C. trachomatis* serovar L2. At the indicated times postinfection, total RNA and DNA were collected from duplicate wells (60). Briefly, total RNA was collected from infected cells using the TRIzol reagent and extracted with chloroform, and the aqueous phase was precipitated with an equal volume of isopropanol, according to the manufacturer's instructions (Thermo Fisher). DNA was removed from total RNA by rigorous DNA-free treatment (Thermo Fisher) before 1 μ g was reverse transcribed with Superscript III reverse transcriptase (RT; Thermo Fisher). Equal volumes of cDNA were used for qPCR. Total DNA was collected from infected cells by trypsinizing the cells, pelleting for 5 min at 400 \times g, and resuspending in phosphate-buffered saline (PBS). Samples were freeze-thawed three times before processing with the DNeasy blood and tissue kit, according to the manufacturer's instructions (Qiagen). One hundred fifty nanograms of total DNA was used for qPCR. Transcripts and genomic DNA were quantified by qPCR in 25- μ l reaction mixtures using 2 \times SYBR green master mix in an ABI7300 thermal cycler in comparison to a standard curve generated from purified *C. trachomatis* L2 genomic DNA. Transcripts were normalized to genomic DNA.

***C. trachomatis* propagation and detection of Clp proteins.** DFCT28, a green fluorescent protein (GFP)-expressing *C. trachomatis* 434/Bu clone (62), was routinely grown in and the titer was determined (using the IFU assay) on HeLa cells (63). Briefly, cells were maintained in Dulbecco's modified Eagle medium (DMEM) supplemented with 10% fetal bovine serum (FBS) and grown at 37°C with 5% CO₂. For chlamydial infection experiments, HeLa cells were grown until confluent in 6-well tissue culture dishes and then infected with DFCT28 at a multiplicity of infection (MOI) of \sim 3 using centrifugation at 545 \times g for 1 h. The infected cells were then incubated at 37°C with 5% CO₂ with DMEM-FBS supplemented with 0.2 μ g/ml cycloheximide and 1 \times nonessential amino acids. At various times postinfection, the medium was removed, cells were washed twice with 2 ml of PBS, and cells were lysed via the addition of 200 μ l Laemmli buffer with β -mercaptoethanol, followed by heating at 90 to 100°C for 5 min. Chlamydial protein samples or purified recombinant ClpP samples were run on 12% SDS-PAGE gels and either stained for total protein with Coomassie brilliant blue or transferred to nitrocellulose for Western blotting. Blots were probed with a rabbit polyclonal anti-*P. aeruginosa* ClpP1 (*Pseudomonas aeruginosa* designation, similar to ClpP2 from *C. trachomatis*) diluted 1:10,000 in 5% milk Tris-buffered saline (mTBS) or anti-*P. aeruginosa* Clp2 (*Pseudomonas aeruginosa* designation, similar to ClpP1 from *C. trachomatis*) at 1:2,500. The antibodies were kindly provided by T. Baker (Massachusetts Institute of Technology) (24). Mouse polyclonal antibodies against chlamydial ClpP1, ClpC, and ClpX (kind gift of G. Zhong, University of Texas Health Sciences Center at San Antonio) were diluted 1:2,000 in mTBS. After incubating with primary antibodies, blots were washed with Tween (0.5%)-TBS (TTBS) and then probed with a goat anti-rabbit IgG poly-horse radish peroxidase (poly-HRP)-conjugated secondary antibody (32260; Thermo Scientific) diluted 1:1,000 in mTBS or goat anti-mouse IgG HRP-conjugated secondary antibody (catalog no. AP124P; Millipore) diluted 1:2,000 in mTBS. As a control for chlamydial protein, blots were also probed for the major outer membrane protein (MOMP) using a mouse monoclonal anti-MOMP antibody (1:1,000, ab41193; Abcam) and a goat anti-mouse IgG HRP-conjugated secondary antibody, as described above. After incubation with the secondary antibodies, blots were washed with TTBS, followed by TBS, and then incubated with chemiluminescent substrate (EMD Millipore Immobilon ECL substrate) for imaging on a Bio-Rad ChemiDoc MP system.

Bioinformatics analysis. Gene maps and sequences of genes of *Chlamydia trachomatis* used were obtained from the STDGen database (<http://stdgen.northwestern.edu>). RefSeq protein sequences from *E. coli*, *B. subtilis*, *M. tuberculosis*, and *P. aeruginosa* were acquired from the NCBI protein database (<https://www.ncbi.nlm.nih.gov/guide/proteins/>). Multiple-sequence alignments were performed using Clustal Omega (64), with default settings, and were presented using Jalview version 2 (65, 73). PDB files for predicted three-dimensional (3D) structures were acquired from the Phyre² website (<http://www.sbg.bio.ic.ac.uk/phyre2/html/page.cgi?id=index>) (66). Protein models and model alignments were rendered

using the UCSF Chimera package from the Computer Graphics Laboratory, University of California, San Francisco (supported by NIH grant P41 RR-01081) (67).

Plasmid construction. A full list of the primers and plasmids used is included in the supplemental material (Table S1). Plasmids for the bacterial adenylate cyclase-based two-hybrid (BACTH) system were cloned using the Gateway recombination system (68). The genes were amplified from *Chlamydia trachomatis* L2 genomic DNA with primers designed to add an *attB* recombination site on either side of the gene. The PCR products were then incubated with a pDONR221 entry vector (containing *attP* recombination sites) in the presence of BP Clonase II (Invitrogen) that inserts the gene via the flanking *attB* sites and removes *ccdB* endotoxin flanked by the *attP* sites encoded on the plasmid, allowing for positive selection. The result of the BP reaction was an entry vector containing the gene of interest flanked by *attL* sites. Two microliters was transformed into *E. coli* DH5 α chemically competent cells and plated onto an LB agar plate containing 50 μ g/ml kanamycin. Plasmid from an individual colony was purified and used for the LR reaction into one of three destination vectors (pST25-DEST, pSNT25-DEST, or pUT18C-DEST). The same entry vector for any given gene was used for all three LR reactions to insert into the destination vector with LR Clonase II. One hundred fifty nanograms of the entry vector was incubated with 150 ng of destination vector for 1 h at room temperature. Two microliters was used to transform *E. coli* XL1 cells, which were plated on the appropriate selection plate. Purified plasmid from an individual colony was sequence verified prior to use in the BACTH assay (see below).

Constructs for chlamydial transformation were created using the HiFi Cloning (New England Biolabs) protocol. To add the C-terminal 6 \times His tag to the Clp proteins, the genes were amplified from the genome with a primer to add the polyhistidine tag. These products served as the template for PCRs to add the necessary overlap for the HiFi reaction. Primers were generated using the NEBuilder assembly tool available from New England BioLabs. The backbone used was the pTLR2 derivative of the pASK plasmid (34). The pTLR2 backbone was digested using FastDigest BshTI and Eco52I restriction enzymes and dephosphorylated using FastAP (Thermo Fisher), and then 25 ng of digested plasmid was incubated with a 2:1 ratio of insert copy number to backbone and 2 \times HiFi master mix (NEB). Following a 15-min incubation of the reaction mixture at 50°C, 2 μ l of the reaction mixture was transformed into *E. coli* DH5 α chemically competent cells (NEB) and plated on the appropriate antibiotic selection plate. Positive clone sequences were verified by Eurofins Genomics. Sequence-verified plasmids were transformed into *E. coli* *dam*[−]/*dcm*[−] competent cells (New England BioLabs) in order to produce demethylated plasmid, which was sequence and digest verified prior to transformation into *C. trachomatis* (see below).

The strains created or used in this study are listed in the supplemental material. *E. coli* strains were maintained on LB agar plates and grown in LB medium or on LB agar plates supplemented with 100 μ g/ml ampicillin as needed. Chlamydial genomic DNA for cloning was obtained from EBs using a phenol-chloroform extraction after extensive heat treatment in the presence of proteinase K (69), and *E. coli* genomic DNA was isolated using sodium hydroxide lysis of colonies. The chlamydial *clpP1* and *clpP2* genes along with *clpP* from *E. coli* were amplified via PCR using the primers listed in the supplemental material and Phusion DNA polymerase (Thermo Scientific). PCR products were cloned into the pLATE31 expression vector from Thermo Scientific, as directed by the manufacturer, to create fusion proteins with a C-terminal 6 \times His tag. Plasmids were initially transformed into *E. coli* NEB10 and selected on LB agar-ampicillin plates. Transformants were screened for inserts using colony PCR with Fermentas master mix (Thermo Scientific), and positive clones were grown for plasmid isolation (GeneJET plasmid miniprep kit; Thermo Scientific). DNA inserts were sequenced by MacroGen USA, and sequence-verified plasmids were then transformed into *E. coli* BL21(DE3) bacteria for protein production.

Chlamydial transformation. The protocol followed was a modification of the method developed by Mueller et al. (70). For transformation, 10⁶ *C. trachomatis* serovar L2 EBs (25667R) naturally lacking the endogenous plasmid were incubated with 2 μ g of unmethylated plasmid in a volume of 50 μ l CaCl₂ at room temperature for 30 min. Each reaction was sufficient for a confluent monolayer of McCoy cells in one well of a six-well plate that had been plated a day prior. The transformants were added to a 1-ml overlay of room temperature Hanks' balanced salt solution (HBSS) per well, and an additional 1 ml of HBSS was then added to each well. The plate was centrifuged at 400 \times g for 15 min at room temperature, and the beginning of this step was recorded as the time of infection. Following the spin, the plate was incubated for 15 min at 37°C. This infection was recorded as T₀. The inoculum was aspirated at the end of the incubation and replaced with antibiotic-free DMEM plus 10% FBS. At 8 h postinfection, the medium was replaced with DMEM containing 1 μ g/ml cycloheximide, 10 μ g/ml gentamicin, and 1 U/ml penicillin. Cells infected with transformants were passaged every 48 h until a population of penicillin-resistant bacteria was established. These EBs were then harvested and frozen in sucrose-phosphate (2SP) (61) solution at −80°C prior to titration.

Determining the effect of overexpression of wild-type and mutant Clp proteins via immunofluorescence and inclusion-forming unit analyses. Transformed *C. trachomatis* cells containing a mutant *clp* gene under the control of an aTc-inducible promoter was used to infect a monolayer of HEp2 cells on coverslips with penicillin as a selection agent. Samples were induced with increasing subtoxic amounts of aTc at 10 h postinfection (hpi) and were methanol fixed after a 14-h pulse (24 hpi). Fixed cells were incubated with an anti-*C. trachomatis* serovar L2 guinea pig primary antibody (kindly provided by E. Rucks, UNMC) to stain for the organism and a goat anti-guinea pig Alexa Fluor 488-conjugated secondary antibody for visualization of organisms within the inclusion. Additionally, a mouse anti-6 \times His tag was used, followed by a goat anti-mouse Alexa Fluor 594-conjugated secondary antibody for confirmation of protein expression and localization. Finally, the samples were stained with 4',6-diamidino-2-phenylindole (DAPI) to visualize the host cell and bacterial DNA. Representative images were taken on a Zeiss LSM 800 confocal laser scanning microscope with a 60 \times objective and 3 \times digital

zoom and were equally color corrected using Adobe Photoshop CC. To assess the effect of wild-type and inactive Clp mutant overexpression via the inclusion-forming unit (IFU) assay, HEp2 monolayers were infected as described above. At 10 hpi, samples either were induced or not with a 10 nM aTc concentration. Infections were allowed to proceed for another 14 h (24 hpi) prior to harvest. To harvest IFUs, sample wells were scraped in 2SP and lysed by vortexing with three 1-mm glass beads for 45 s. Samples were serially diluted in 2SP and titrated in duplicate directly onto a new monolayer of HEp2 cells. Following 24 h of incubation, the samples were fixed and stained with an anti-*C. trachomatis* serovar L2 guinea pig primary and Alexa Fluor 488-conjugated secondary antibodies. Fifteen fields of view were counted for each duplicate well, giving a total of 30 fields of view per experiment. Three independent replicates were performed, and the totals for each experiment were averaged. Values were expressed as a percentage of the uninduced sample to provide an internal control. Student's two-tailed *t* test to compare the induced samples to the uninduced control was performed using the averages of each biological replicate.

Determining protein-protein interactions with the BACTH system. To test interactions of the Clp proteins, the BACTH assay was utilized. This assay relies on reconstitution of adenylate cyclase activity in adenylate cyclase-deficient (Δ cya) DHT1 *E. coli* mutant strain. The genes of interest are translationally fused to one of either subunit, denoted T18 and T25, of the *B. pertussis* adenylate cyclase toxin. Each wild-type or mutant *clp* gene cloned into one of the pST25, pSNT25, or pUT18C Gateway vectors was tested for both homotypic and heterotypic interactions (8). One plasmid from the T25 background and one from the T18 background were cotransformed into the *E. coli* DHT1 CaCl_2 competent cells and were plated on a double-antibiotic minimal M63 medium selection plate supplemented with 0.5 mM isopropyl thio- β -D-galactopyranoside (IPTG) for induction of the protein, 40 $\mu\text{g}/\text{ml}$ X-Gal to give a visual readout upon cleavage, and 0.2% maltose as a unique carbon source. These plates also contain 0.04% casein hydrolysate to supplement the bacteria with the branched-chain amino acids, as *E. coli* DHT1 Δ cya cannot synthesize these amino acids. Blue colonies were indicative of positive interaction between proteins, since both the *lac* and *mal* operons require reconstituted cAMP production from interacting T25 and T18 fragments to be expressed. Leucine zipper motifs were used for controls in pKT25 and pUT18C backgrounds on the appropriate antibiotic selection plates because these have been previously shown to interact (71). β -Galactosidase activity was then measured from 8 colonies to quantify protein interactions. Random positive colonies were used to inoculate individual wells and grown 24 h at 30°C in M63 with 0.2% maltose and the appropriate antibiotics. These bacteria were permeabilized with 0.1% SDS and chloroform prior to the addition of 0.1% o-nitrophenol- β -galactoside (ONPG). The reaction was stopped using 1 M NaHCO_3 after precisely 20 min of incubation at room temperature. Absorbance at the 405 wavelength was recorded and normalized to bacterial growth (optical density at 600 nm [OD_{600}]), dilution factor, and time (in minutes) of incubation prior to stopping the reaction. Totals were reported in relative units (RU) of β -galactosidase activity.

Purification of recombinant wild-type and mutant ClpP proteins. His-tagged *C. trachomatis* ClpP1, *C. trachomatis* ClpP1(S92A), *C. trachomatis* ClpP1(M6L-M7I), *C. trachomatis* ClpP2, *C. trachomatis* ClpP2(S98A), and *E. coli* ClpP were purified from 500-ml cultures of *E. coli* BL21(DE3) transformed with the respective plasmid based on the protocol described in reference 72. Samples were induced with 0.5 mM IPTG and incubated with shaking for 20 h at 18°C. Cultures were pelleted and frozen at -20°C prior to purifications. The buffers used are listed in Table S2. Samples were suspended, sonicated, bound to HisPur cobalt resin (Thermo Scientific), and washed in buffer A. Proteins were eluted from the resin using buffer B. Buffer exchange for buffer C was performed using a Millipore Amicon Ultra-15 filtration unit (3-kDa cutoff). ClpP proteins were quantified using the Bio-Rad protein assay, assessed for purity on 12% SDS-PAGE gels with Coomassie staining, and identified using anti-His tag Western blotting. Blotting was performed using a mouse monoclonal anti-6 \times His antibody (1:1,000; Millipore HIS.H8) and a goat anti-mouse IgG HRP-conjugated secondary antibody (1:2,000). Protein samples were aliquoted and stored at -80°C .

In vitro analysis of ClpP homo-oligomerization. Five micrograms of purified protein was incubated in buffer D at 37°C for 1 h before being mixed with a 5 \times native sample buffer (5 mM Tris [pH 6.8], 38 mM glycine, 0.06% bromophenol blue) and analyzed on a Bio-Rad MiniPROTEAN 4 to 20% gradient gel for native PAGE. Samples were run for 90 min at 200 V. Gels were assessed using Coomassie staining.

Assessment of ClpP activity in vitro. For the fluorometric peptide assay, the ClpP proteins (at 1 μM monomeric concentration) were added to 500 μM Suc-Luc-Tyr-AMC (Boston Biochem) dissolved in buffer E (50 mM Tris-HCl [pH 8], 200 mM KCl, and 1 mM dithiothreitol [DTT]) or buffer F (with 0.2 M sodium citrate) (42). The final reaction mixture volumes were 50 μl . Reactions were monitored over 6 h at 37°C using a BioTek Synergy HT plate reader set at an excitation of 340/360 and an emission of 440/460, with readings taken at 5-min intervals. For the casein degradation assays, casein (Sigma-Aldrich) was dissolved in buffer E, and 1 μg was used per assay. Samples containing casein and 1 μM the respective ClpP monomer were incubated at 37°C for 3 h with or without the respective ACP compound (500 μM). Reactions were halted by mixing with 2 \times Laemmli buffer containing β -mercaptoethanol and heating at 90 to 100°C for 5 min. Samples were analyzed for digestion of casein using 12% SDS-PAGE gels, followed by Coomassie blue staining.

Effect of ACP compounds on chlamydial growth and host cell viability. Antibiotic stocks of ACP1, ACP1a, and ACP1b were synthesized as described previously (45), resuspended at 25 mg/ml in dimethyl sulfoxide (DMSO), and frozen at -20°C in aliquots to avoid freeze-thawing. The methods for the synthesis, purification, and analysis of these compounds are available in the supplemental material. For assessment of cell viability upon treatment, four wells of a 96-well plate with a confluent monolayer of HEp2 cells were either infected with density gradient-purified wild-type *C. trachomatis* serovar L2 with an

MOI of 1 or left uninfected. These wells were either treated or not with 25 or 50 $\mu\text{g/ml}$ ACP1, ACP1a, or ACP1b, with a set of DMSO-only samples used as a control. Antibiotics were added 8 h postinfection (hpi). At 24 hpi, 100 μl of 2 \times resazurin (Abcam) was added to three wells of each treatment condition, adding only DMEM to the fourth as a background control. Following a 4-h incubation at 37°C, absorbance at the 570-nm wavelength was recorded using a Tecan plate reader. The wells were averaged, subtracting background absorbance from samples without dye. Absorbance was reported as a percentage of the untreated samples. To quantify the effect of the drug on *C. trachomatis*, various treatments of each drug (25 μg and 50 μg) were added or not 8 h postinfection. Cell lysates containing *C. trachomatis* were collected in 2SP and frozen at -80°C prior to serial titration on a fresh cell layer. Inclusion-forming units (IFUs), a proxy for recoverable EBs from the initial infection samples, were calculated from the average number of inclusions in 15 fields of view multiplied by the number of fields of view within the well and corrected for the dilution factor and volume of inoculum.

SUPPLEMENTAL MATERIAL

Supplemental material for this article may be found at <https://doi.org/10.1128/JB.00635-18>.

SUPPLEMENTAL FILE 1, PDF file, 3.1 MB.

ACKNOWLEDGMENTS

We thank Elizabeth Rucks of UNMC for providing us with antibodies for analysis by immunofluorescence and for thoughtful review of the manuscript. We thank Walid Houry (University of Toronto) for providing us with an initial sample of the ACP1b antibiotic, Tania Baker (MIT) for providing us with *P. aeruginosa* ClpP-specific antibodies for use in our experiments, Guangming Zhong (UT San Antonio), and H. Caldwell (NIH/NIAID) for eukaryotic cell lines.

Funding for this project was supported by an NSF CAREER award (1810599) to S.P.O. and University funds to D.J.F. This project was also funded by the Department of Defense office of the Congressionally Directed Medical Research Programs (CDMRP), 2017 Peer Reviewed Medical Research Program (PRMRP) Discovery Award (PR172445) to M.C.-S. Support for the UNMC Advanced Microscopy Core Facility was provided by the Nebraska Research Initiative, the Fred and Pamela Buffett Cancer Center Support Grant (P30CA036727), and an Institutional Development Award (IDeA) from the NIGMS/NIH (grant P30GM106397).

REFERENCES

- Hafner LM, Wilson DP, Timms P. 2014. Development status and future prospects for a vaccine against *Chlamydia trachomatis* infection. *Vaccine* 32:1563–1571. <https://doi.org/10.1016/j.vaccine.2013.08.020>.
- AbdelRahman YM, Belland RJ. 2005. The chlamydial developmental cycle. *FEMS Microbiol Rev* 29:949–959. <https://doi.org/10.1016/j.femsre.2005.03.002>.
- Hackstadt T, Baehr W, Ying Y. 1991. *Chlamydia trachomatis* developmentally regulated protein is homologous to eukaryotic histone H1. *Proc Natl Acad Sci U S A* 88:3937–3941. <https://doi.org/10.1073/pnas.88.9.3937>.
- Hatch TP, Allan I, Pearce JH. 1984. Structural and polypeptide differences between envelopes of infective and reproductive life cycle forms of *Chlamydia* spp. *J Bacteriol* 157:13–20.
- Clifton DR, Fields KA, Grieshaber SS, Dooley CA, Fischer ER, Mead DJ, Carabeo RA, Hackstadt T. 2004. A chlamydial type III translocated protein is tyrosine-phosphorylated at the site of entry and associated with recruitment of actin. *Proc Natl Acad Sci U S A* 101:10166. <https://doi.org/10.1073/pnas.0402829101>.
- Lane BJ, Mutchler C, Al Khodor S, Grieshaber SS, Carabeo RA. 2008. Chlamydial entry involves TARP binding of guanine nucleotide exchange factors. *PLoS Pathog* 4:e1000014. <https://doi.org/10.1371/journal.ppat.1000014>.
- Hodinka RL, Davis CH, Choong J, Wyrick PB. 1988. Ultrastructural study of endocytosis of *Chlamydia trachomatis* by McCoy cells. *Infect Immun* 56:1456–1463.
- Moore ER, Ouellette SP. 2014. Reconceptualizing the chlamydial inclusion as a pathogen-specified parasitic organelle: an expanded role for Inc proteins. *Front Cell Infect Microbiol* 4:157. <https://doi.org/10.3389/fcimb.2014.00157>.
- Belland RJ, Zhong G, Crane DD, Hogan D, Sturdevant D, Sharma J, Beatty WL, Caldwell HD. 2003. Genomic transcriptional profiling of the developmental cycle of *Chlamydia trachomatis*. *Proc Natl Acad Sci U S A* 100:8478–8483. <https://doi.org/10.1073/pnas.1331135100>.
- Vandahl BBS, Birkelund S, Christiansen G. 2004. Genome and proteome analysis of *Chlamydia*. *Proteomics* 4:2831–2842. <https://doi.org/10.1002/pmic.200400940>.
- Skipp PJS, Hughes C, McKenna T, Edwards R, Langridge J, Thomson NR, Clarke IN. 2016. Quantitative proteomics of the infectious and replicative forms of *Chlamydia trachomatis*. *PLoS One* 11:e0149011. <https://doi.org/10.1371/journal.pone.0149011>.
- Saka HA, Thompson JW, Chen Y-S, Kumar Y, Dubois LG, Moseley MA, Valdivia RH. 2011. Quantitative proteomics reveals metabolic and pathogenic properties of *Chlamydia trachomatis* developmental forms. *Mol Microbiol* 82:1185–1203. <https://doi.org/10.1111/j.1365-2958.2011.07877.x>.
- Beatty WL, Byrne GI, Morrison RP. 1993. Morphologic and antigenic characterization of interferon gamma-mediated persistent *Chlamydia trachomatis* infection in vitro. *Proc Natl Acad Sci U S A* 90:3998–4002. <https://doi.org/10.1073/pnas.90.9.3998>.
- Raulston JE. 1997. Response of *Chlamydia trachomatis* serovar E to iron restriction in vitro and evidence for iron-regulated chlamydial proteins. *Infect Immun* 65:4539–4547.
- Matsumoto A, Manire GP. 1970. Electron microscopic observations on the effects of penicillin on the morphology of *Chlamydia psittaci*. *J Bacteriol* 101:278–285.
- Stephens RS, Kalman S, Lammel C, Fan J, Marathe R, Aravind L, Mitchell W, Olinger L, Tatusov RL, Zhao Q, Koonin EV, Davis RW. 1998. Genome sequence of an obligate intracellular pathogen of humans: *Chlamydia trachomatis*. *Science* 282:754. <https://doi.org/10.1126/science.282.5389.754>.
- Stinson BM, Nager AR, Glynn SE, Schmitz KR, Baker TA, Sauer RT. 2013. Nucleotide binding and conformational switching in the hexameric ring

- of a AAA+ machine. *Cell* 153:628–639. <https://doi.org/10.1016/j.cell.2013.03.029>.
18. Kirstein J, Schlothauer T, Dougan DA, Lilie H, Tischendorf G, Mogk A, Bukau B, Turgay K. 2006. Adaptor protein controlled oligomerization activates the AAA+ protein ClpC. *EMBO J* 25:1481–1491. <https://doi.org/10.1038/sj.emboj.7601042>.
 19. Baker TA, Sauer RT. 2012. ClpXP, an ATP-powered unfolding and protein-degradation machine. *Biochim Biophys Acta* 1823:15–28. <https://doi.org/10.1016/j.bbamcr.2011.06.007>.
 20. Alexopoulos JA, Guarné A, Ortega J. 2012. ClpP: a structurally dynamic protease regulated by AAA+ proteins. *J Struct Biol* 179:202–210. <https://doi.org/10.1016/j.jsb.2012.05.003>.
 21. Yu AYH, Houry WA. 2007. ClpP: a distinctive family of cylindrical energy-dependent serine proteases. *FEBS Lett* 581:3749–3757. <https://doi.org/10.1016/j.febslet.2007.04.076>.
 22. Grimaud R, Kessel M, Beuron F, Steven AC, Maurizi MR. 1998. Enzymatic and structural similarities between the *Escherichia coli* ATP-dependent proteases, ClpXP and ClpAP. *J Biol Chem* 273:12476–12481. <https://doi.org/10.1074/jbc.273.20.12476>.
 23. Bewley MC, Graziano V, Griffin K, Flanagan JM. 2006. The asymmetry in the mature amino-terminus of ClpP facilitates a local symmetry match in ClpAP and ClpXP complexes. *J Struct Biol* 153:113–128. <https://doi.org/10.1016/j.jsb.2005.09.011>.
 24. Hall BM, Breidenstein EBM, de la Fuente-Núñez C, Reffuveille F, Mawla GD, Hancock REW, Baker TA. 2017. Two isoforms of Clp peptidase in *Pseudomonas aeruginosa* control distinct aspects of cellular physiology. *J Bacteriol* 199:e00568-16.
 25. Akopian T, Kandror O, Raju RM, Unnikrishnan M, Rubin EJ, Goldberg AL. 2012. The active ClpP protease from *M. tuberculosis* is a complex composed of a heptameric ClpP1 and a ClpP2 ring. *EMBO J* 31:1529–1541. <https://doi.org/10.1038/emboj.2012.5>.
 26. Dahmen M, Vielberg M-T, Groll M, Sieber Stephan A. 2015. Structure and mechanism of the caseinolytic protease ClpP1/2 heterocomplex from *Listeria monocytogenes*. *Angew Chem Int Ed Engl* 54:3598–3602. <https://doi.org/10.1002/anie.201409325>.
 27. Balogh D, Dahmen M, Stahl M, Poreba M, Gersch M, Drag M, Sieber SA. 2017. Insights into ClpXP proteolysis: heterooligomerization and partial deactivation enhance chaperone affinity and substrate turnover in *Listeria monocytogenes*. *Chem Sci* 8:1592–1600. <https://doi.org/10.1039/c6sc03438a>.
 28. Shaw EI, Dooley CA, Fischer ER, Scidmore MA, Fields KA, Hackstadt T. 2000. Three temporal classes of gene expression during the *Chlamydia trachomatis* developmental cycle. *Mol Microbiol* 37:913–925. <https://doi.org/10.1046/j.1365-2958.2000.02057.x>.
 29. Wichlan DG, Hatch TP. 1993. Identification of an early-stage gene of *Chlamydia psittaci* 6BC. *J Bacteriol* 175:2936–2942. <https://doi.org/10.1128/jb.175.10.2936-2942.1993>.
 30. Douglas AL, Hatch TP. 2000. Expression of the transcripts of the sigma factors and putative sigma factor regulators of *Chlamydia trachomatis* L2. *Gene* 247:209–214. [https://doi.org/10.1016/S0378-1119\(00\)00094-9](https://doi.org/10.1016/S0378-1119(00)00094-9).
 31. Ouellette SP, Rueden KJ, Gauliard E, Persons L, de Boer PA, Ladant D. 2014. Analysis of MreB interactors in *Chlamydia* reveals a RodZ homolog but fails to detect an interaction with MraY. *Front Microbiol* 5:279. <https://doi.org/10.3389/fmicb.2014.00279>.
 32. Martin A, Baker TA, Sauer RT. 2008. Diverse pore loops of the AAA+ ClpX machine mediate unassisted and adaptor-dependent recognition of ssrA-tagged substrates. *Mol Cell* 29:441–450. <https://doi.org/10.1016/j.molcel.2008.02.002>.
 33. Ni T, Ye F, Liu X, Zhang J, Liu H, Li J, Zhang Y, Sun Y, Wang M, Luo C, Jiang H, Lan L, Gan J, Zhang A, Zhou H, Yang C-G. 2016. Characterization of gain-of-function mutant provides new insights into ClpP structure. *ACS Chem Biol* 11:1964–1972. <https://doi.org/10.1021/acschembio.6b00390>.
 34. Wickström J, Sammons LR, Restivo KN, Hefty PS. 2013. Conditional gene expression in *Chlamydia trachomatis* using the Tet system. *PLoS One* 8:e76743. <https://doi.org/10.1371/journal.pone.0076743>.
 35. Feng J, Michalik S, Varming AN, Andersen JH, Albrecht D, Jelsbak L, Krieger S, Ohlsen K, Hecker M, Gerth U, Ingmer H, Frees D. 2013. Trapping and proteomic identification of cellular substrates of the ClpP protease in *Staphylococcus aureus*. *J Proteome Res* 12:547–558. <https://doi.org/10.1021/pr300394r>.
 36. Rucks EA, Olson MG, Jorgenson LM, Srinivasan RR, Ouellette SP. 2017. Development of a proximity labeling system to map the *Chlamydia trachomatis* inclusion membrane. *Front Cell Infect Microbiol* 7:40. <https://doi.org/10.3389/fcimb.2017.00040>.
 37. Ouellette SP. 2018. Feasibility of a conditional knockout system for *Chlamydia* based on CRISPR interference. *Front Cell Infect Microbiol* 8:59. <https://doi.org/10.3389/fcimb.2018.00059>.
 38. Joshi SA, Hersch GL, Baker TA, Sauer RT. 2004. Communication between ClpX and ClpP during substrate processing and degradation. *Nat Struct Mol Biol* 11:404. <https://doi.org/10.1038/nsmb752>.
 39. Schmitz KR, Carney DW, Sello JK, Sauer RT. 2014. Crystal structure of *Mycobacterium tuberculosis* ClpP1P2 suggests a model for peptidase activation by AAA+ partner binding and substrate delivery. *Proc Natl Acad Sci U S A* 111:E4587–E4595. <https://doi.org/10.1073/pnas.1417120111>.
 40. Karimova G, Pidoux J, Ullmann A, Ladant D. 1998. A bacterial two-hybrid system based on a reconstituted signal transduction pathway. *Proc Natl Acad Sci U S A* 95:5752–5756. <https://doi.org/10.1073/pnas.95.10.5752>.
 41. Woo KM, Chung WJ, Ha DB, Goldberg AL, Chung CH. 1989. Protease Ti from *Escherichia coli* requires ATP hydrolysis for protein breakdown but not for hydrolysis of small peptides. *J Biol Chem* 264:2088–2091.
 42. Gersch M, Stahl M, Poreba M, Dahmen M, Dziedzic A, Drag M, Sieber SA. 2016. Barrel-shaped ClpP proteases display attenuated cleavage specificity. *ACS Chem Biol* 11:389–399. <https://doi.org/10.1021/acschembio.5b00757>.
 43. Brötz-Oesterhelt H, Beyer D, Kroll H-P, Endermann R, Ladel C, Schroeder W, Hinzen B, Raddatz S, Paulsen H, Henninger K, Bandow JE, Sahl H-G, Labischinski H. 2005. Dysregulation of bacterial proteolytic machinery by a new class of antibiotics. *Nat Med* 11:1082. <https://doi.org/10.1038/nm1306>.
 44. Conlon BP, Nakayasu ES, Fleck LE, LaFleur MD, Isabella VM, Coleman K, Leonard SN, Smith RD, Adkins JN, Lewis K. 2013. Killing persister cells and eradicating a biofilm infection by activating the ClpP protease. *Nature* 503:365–370. <https://doi.org/10.1038/nature12790>.
 45. Leung E, Datti A, Cossette M, Goodreid J, McCaw SE, Mah M, Nakhamchik A, Ogata K, El Bakkouri M, Cheng Y-Q, Wodak SJ, Eger BT, Pai EF, Liu J, Gray-Owen S, Batey RA, Houry WA. 2011. Activators of cylindrical proteases as antimicrobials: identification and development of small molecule activators of ClpP protease. *Chem Biol* 18:1167–1178. <https://doi.org/10.1016/j.chembiol.2011.07.023>.
 46. Hwang BJ, Park WJ, Chung CH, Goldberg AL. 1987. *Escherichia coli* contains a soluble ATP-dependent protease (Ti) distinct from protease La. *Proc Natl Acad Sci U S A* 84:5550–5554. <https://doi.org/10.1073/pnas.84.16.5550>.
 47. Flanagan JM, Wall JS, Capel MS, Schneider DK, Shanklin J. 1995. Scanning transmission electron microscopy and small-angle scattering provide evidence that native *Escherichia coli* ClpP is a tetradecamer with an axial pore. *Biochemistry* 34:10910–10917. <https://doi.org/10.1021/bi00034a025>.
 48. Wang J, Hartling JA, Flanagan JM. 1997. The structure of ClpP at 2.3 Å resolution suggests a model for ATP-dependent proteolysis. *Cell* 91:447–456. [https://doi.org/10.1016/S0092-8674\(00\)80431-6](https://doi.org/10.1016/S0092-8674(00)80431-6).
 49. Lee ME, Baker TA, Sauer RT. 2010. Control of substrate gating and translocation into ClpP by channel residues and ClpX binding. *J Mol Biol* 399:707–718. <https://doi.org/10.1016/j.jmb.2010.04.027>.
 50. Thompson MW, Singh SK, Maurizi MR. 1994. Processive degradation of proteins by the ATP-dependent Clp protease from *Escherichia coli*. Requirement for the multiple array of active sites in ClpP but not ATP hydrolysis. *J Biol Chem* 269:18209–18215.
 51. Jennings LD, Bohon J, Chance MR, Licht S. 2008. The ClpP N terminus coordinates substrate access with protease active site reactivity. *Biochemistry* 47:11031–11040. <https://doi.org/10.1021/bi8010169>.
 52. Benaroudj N, Raynal B, Miot M, Ortiz-Lombardia M. 2011. Assembly and proteolytic processing of mycobacterial ClpP1 and ClpP2. *BMC Biochem* 12:61. <https://doi.org/10.1186/1471-2091-12-61>.
 53. Gaillot O, Bregenholt S, Jaubert F, Di Santo JP, Berche P. 2001. Stress-induced ClpP serine protease of *Listeria monocytogenes* is essential for induction of listeriolysin O-dependent protective immunity. *Infect Immun* 69:4938–4943. <https://doi.org/10.1128/IAI.69.8.4938-4943.2001>.
 54. Martin A, Baker TA, Sauer RT. 2007. Distinct static and dynamic interactions control ATPase-peptidase communication in a AAA+ protease. *Mol Cell* 27:41–52. <https://doi.org/10.1016/j.molcel.2007.05.024>.
 55. Lee B-G, Park EY, Lee K-E, Jeon H, Sung KH, Paulsen H, Rübsamen-Schaeff H, Brötz-Oesterhelt H, Song HK. 2010. Structures of ClpP in complex with acyldepsipeptide antibiotics reveal its activation mechanism. *Nat Struct Mol Biol* 17:471. <https://doi.org/10.1038/nsmb.1787>.
 56. Bewley MC, Graziano V, Griffin K, Flanagan JM. 2009. Turned on for

- degradation: ATPase-independent degradation by ClpP. *J Struct Biol* 165:118–125. <https://doi.org/10.1016/j.jsb.2008.10.005>.
57. Li DHS, Chung YS, Gloyd M, Joseph E, Ghirlando R, Wright GD, Cheng Y-Q, Maurizi MR, Guarné A, Ortega J. 2010. Acyldepsipeptide antibiotics induces the formation of a structured axial channel in ClpP: a model for the ClpX/ClpA bound state of ClpP. *Chem Biol* 17:959–969. <https://doi.org/10.1016/j.chembiol.2010.07.008>.
 58. Ouellette SP, Dorsey FC, Moshiah S, Cleveland JL, Carabeo RA. 2011. *Chlamydia* species-dependent differences in the growth requirement for lysosomes. *PLoS One* 6:e16783. <https://doi.org/10.1371/journal.pone.0016783>.
 59. Kane CD, Vena RM, Ouellette SP, Byrne GI. 1999. Intracellular tryptophan pool sizes may account for differences in gamma interferon-mediated inhibition and persistence of chlamydial growth in polarized and non-polarized cells. *Infect Immun* 67:1666–1671.
 60. Ouellette SP, Rueden KJ, Rucks EA. 2016. Tryptophan codon-dependent transcription in *Chlamydia pneumoniae* during gamma interferon-mediated tryptophan limitation. *Infect Immun* 84:2703–2713. <https://doi.org/10.1128/IAI.00377-16>.
 61. Wang Y, Kahane S, Cutcliffe LT, Skilton RJ, Lambden PR, Clarke IN. 2011. Development of a transformation system for *Chlamydia trachomatis*: restoration of glycogen biosynthesis by acquisition of a plasmid shuttle vector. *PLoS Pathog* 7:e1002258. <https://doi.org/10.1371/journal.ppat.1002258>.
 62. Illingworth M, Hooppaw AJ, Ruan L, Fisher DJ, Chen L. 2017. Biochemical and genetic analysis of the *Chlamydia* GroEL chaperonins. *J Bacteriol* 199:e00844-16.
 63. Scidmore MA. 2006. Cultivation and laboratory maintenance of *Chlamydia trachomatis*. *Curr Protoc Microbiol* Chapter 11:Unit11A.1.
 64. Sievers F, Wilm A, Dineen D, Gibson TJ, Karplus K, Li W, Lopez R, McWilliam H, Remmert M, Söding J, Thompson JD, Higgins DG. 2011. Fast, scalable generation of high-quality protein multiple sequence alignments using Clustal Omega. *Mol Syst Biol* 7:539. <https://doi.org/10.1038/msb.2011.75>.
 65. Troshin PV, Procter JB, Barton GJ. 2011. Java bioinformatics analysis web services for multiple sequence alignment—JABAWS:MSA. *Bioinformatics* 27:2001–2002. <https://doi.org/10.1093/bioinformatics/btr304>.
 66. Kelley LA, Mezulis S, Yates CM, Wass MN, Sternberg MJE. 2015. The Phyre2 web portal for protein modelling, prediction and analysis. *Nat Protoc* 10:845–858. <https://doi.org/10.1038/nprot.2015.053>.
 67. Pettersen EF, Goddard TD, Huang CC, Couch GS, Greenblatt DM, Meng EC, Ferrin TE. 2004. UCSF Chimera—a visualization system for exploratory research and analysis. *J Comput Chem* 25:1605–1612. <https://doi.org/10.1002/jcc.20084>.
 68. Ouellette SP, Gauliard E, Antosová Z, Ladant D. 2014. A Gateway-compatible bacterial adenylate cyclase-based two-hybrid system. *Environ Microbiol Rep* 6:259–267. <https://doi.org/10.1111/1758-2229.12123>.
 69. Ouellette SP, Hatch TP, AbdelRahman YM, Rose LA, Belland RJ, Byrne GI. 2006. Global transcriptional upregulation in the absence of increased translation in *Chlamydia* during IFN γ -mediated host cell tryptophan starvation. *Mol Microbiol* 62:1387–1401. <https://doi.org/10.1111/j.1365-2958.2006.05465.x>.
 70. Mueller KE, Wolf K, Fields KA. 2017. *Chlamydia trachomatis* transformation and allelic exchange mutagenesis. *Curr Protoc Microbiol* 45:11A.3.1–11A.3.15.
 71. Robichon C, Karimova G, Beckwith J, Ladant D. 2011. Role of leucine zipper motifs in association of the *Escherichia coli* cell division proteins FtsL and FtsB. *J Bacteriol* 193:4988–4992. <https://doi.org/10.1128/JB.00324-11>.
 72. Trentini DB, Suskiewicz MJ, Heuck A, Kurzbauer R, Deszcz L, Mechtler K, Clausen T. 2016. Arginine phosphorylation marks proteins for degradation by a Clp protease. *Nature* 539:48. <https://doi.org/10.1038/nature20122>.
 73. Altschul SF, Wootton JC, Gertz EM, Agarwala R, Morgulis A, Schäffer AA, Yu Y-K. 2005. Protein database searches using compositionally adjusted substitution matrices. *FEBS J* 272:5101–5109. <https://doi.org/10.1111/j.1742-4658.2005.04945.x>.

Submissions Being Processed for Author martin conda-sheridan, Ph.D.

Page: 1 of 1 (1 total submissions)

Display results per page.

Action	Manuscript Number	Title	Initial Date Submitted	Status Date	Current Status
Action Links	PEPTIDES-D-19-00190	Understanding interactions of Citropin 1.1 analogs with model membranes and their influence on biological activity	May 15, 2019	May 28, 2019	Under Review

Page: 1 of 1 (1 total submissions)

Display results per page.

<< Author Main Menu